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AID activation induced cytidine deaminase
AP-site apurinic or apyrimidinic site in a DNA strand
BER base excision repair
C immunoglobulin constant region
CSR class switch recombination
D diversity gene segment
Eµ large heavy chain Ig intronic enhancer
H heavy chain
HIGM2 hyper-IgM syndrome 2
HNPCC hereditary nonpolyposis colorectal cancer
Ig immunglobulin
J joining gene segment
κ3' kappa chain 3' enhancer
κi kappa chain intronic enhancer
L light chain
MAR matrix attachment region
MMR mismatch repair
mutator mutator enzyme complex
RAG recombination-activating gene
RPA replication protein A
SHM somatic hypermutation
UNG uracil DNA glycosylase
V variable gene segment
1. Introduction
This thesis focuses on the genetic elements and molecular mechanisms involved in
somatic hypermutation of the immunoglobulin (Ig) locus. On the basis of theoretical
considerations, it was first suggested by Lederberg in 1959, that somatic hypermutation is
one of the generators of antibody diversity [Lederberg, 1959]. The first concrete
experimental evidence for this was provided much later by Weigert et al. in 1970, before
the primary and secondary repertoires were distinguished in molecular terms [Weigert et
al., 1970]. When a B cell is activated by antigen contact, it can home in the germinal
centers of the follicles of lymphoid organs (i.e. spleen, tonsils, Peyer's patches). There the
gene segments encoding the variable region (V-region) of the B cell receptor may be
mutated at a high rate [Wabl et al., 1999]. Some of these mutations may change the
affinity of the receptor, and B cells with a higher affinity to the antigen are selected and
proliferate. Thus, hypermutation contributes to the so-called "affinity maturation" of
activated B-cells and creates the secondary repertoire.
The primary antibody repertoire is generated during early B-lymphocyte development by
the rearrangement of the V, D, and J gene segments at the Ig heavy (H) chain locus, and
the V, J rearrangement of the light (L) chain gene segments [Tonegawa, 1983]. This
process is mediated by the products of the lymphoid specific recombination-activating
genes 1 (RAG-1) and 2 (RAG-2) [Hesslein and Schatz, 2001]. A naïve (pre-immune) B-
cell repertoire is thus generated by various diversifiers: (i) combination of different H and
L chains; (ii) combination of different gene segments; (iii) and junctional diversity at the
ligation sites of the gene segments.
However, the primary B-cell repertoire generates B cell receptors and antibodies with
rather low affinity to antigen structures. High affinity antibodies are generated mainly in
the secondary repertoire through hypermutation, after a B cell has been activated, but
before they differentiate into plasma or memory cells. In this process, point mutations are
introduced at high rates at the Ig locus. The mutation rate is a million fold higher than the
estimated spontaneous mutation rate of 10-9 to 10-10 per bp per cell generation, at other
loci of the genome [McKean et al., 1884; Allen et al., 1987; Berek et al., 1991]. The
mutations that are created by hypermutation are largely restricted to nucleotide
substitutions rather than deletions and insertions. A comparison of hypermutated DNA
sequences from an Ig database revealed sites of even higher intrinsic mutability than
others; these are called hot spots, with the consensus sequence motif RGYW (R = A or
G; Y = C or T; W = A or T) [Rogozin and Kolchanov, 1992; Betz et al., 1993; Jolly et
al., 1996; Rogozin et al., 1996]. It was reasoned that hypermutation at the Ig genes is a
paradigm of a site-specific, stage-specific, and lineage-specific "mutator system" that
generates point mutations [Wabl et al., 1985]. Indeed, at the Ig locus the mutator action is
restricted to a 2 kb stretch compassing the rearranged VDJ or VJ sequences of the
endogenous Ig genes [Neuberger and Milstein, 1995]. The 5' boundary of this stretch is
well defined by the transcriptional start site of the Ig promotor; the 3' boundary near the
Ig intronic enhancer is more loosely defined [Gearhart et al., 1981; Gearhart and
Bogenhagen, 1983]. Surprisingly, the V-region is not absolutely necessary for triggering
hypermutation as shown by Milstein, Neuberger and colleagues in transgenic constructs
where they substituted the Ig V-regions by reporter genes, like gpt or neor [Yelamos et
al., 1995]. Still, the RGYW motif is a mutational hot spot in these reporter genes. Later,
the hot spot motif was confirmed by actual experimentation [Bachl et al., 1997]. From
the beginning, and still to date, the questions the field has been trying to answer are:
What are the cis-acting and trans-acting elements, and what kind of molecular
mechanisms are active in somatic hypermutation?
1.1. Cis-acting elements in somatic hypermutation
There are many reviews that cover the cis-acting genetic elements involved in
hypermutation [Klein et al., 1998; Kong et al., 1998; Neuberger et al., 1998; Storb  et al.,
1998; Winter and Gearhart, 1998]. It is well known that transcription is necessary for
driving hypermutation. In an inducible system, Bachl et al. [Bachl et al., 2001] showed
that hypermutation rates correlate with transcription rates, but that transcription does not
have to be driven by the Ig promoter [Bachl et al., 1998; Bachl et al., 2001]. Apart from
the promoter, for full hypermutation either of the large Ig intronic enhancers (Eµ or Ekappa
enhancer) and an additional 3' enhancer were suggested to be sufficient to target the
mutator [Betz et al., 1994; Bachl et al., 1998]. Again, the 3' enhancer has not necessarily
to be the 3' Ig enhancer; but without it hypermutation occurs at a lower rate [Bachl and
Olsson, 1999]. At the beginning of this study, it seemed that the Eµ enhancer, in the right
distance and orientation to the gene to be mutated, is the only Ig-locus specific sequence
required to recruit the trans-acting factors for hypermutation [Bachl et al., 1998]. This
was shown by Bachl and Olsson [Bachl and Olsson, 1999] in experiments, where the
large intronic enhancer was placed next to a green fluorescence protein (GFP) to confer
hypermutability, without any other Ig sequence present nearby.
The experiments described above are consistent with the notion that hypermutation of Ig
genes is the prime example for site directed mutagenesis. However, because several non-
Ig genes (i.e. BCL-6, B29 and mb1, CD95) have been reported to hypermutate in
activated B-cells [Shen et al., 1998; Gordon et al., 2003; Müschen et al., 2002], the site-
specificity of the mutator action has been challenged. On the other hand, selected house
keeping genes in activated B cells show no indication of increased mutability [Shen et al.,
2000]. To fit these results into the general view of site-directed hypermutation in Ig
genes, it was hypothesized that the non-Ig loci would contain unidentified Ig-like cis-
acting regulatory sequences, which would allow the targeting of the mutator complex.
However, non-Ig enhancers have not been tested extensively enough to exclude their
activity of targeting the mutator, nor have the intronic Ig enhancer, or any other enhancer,
been trimmed to the minimal sequence sufficient for hypermutation.
1.2. Trans-acting factors in somatic hypermutation
1.2.1. Activation-induced cytidine deaminase (AID)
At the beginning of this study, not much was known about the trans-acting factors and
the molecular mechanisms involved in hypermutation, which gave rise for several
intriguing hypotheses [e.g. Manser, 1990; Rogerson et al., 1991; Gearhart, 1983]. It was
the discovery of the activation-induced cytidine deaminase (AID) and its absolute
requirement for somatic hypermutation, which triggered the recent progress in the field
[Muramatsu et al., 1999; Muramatsu et al., 2000]. AID is exclusively expressed in
activated B cells of the germinal center; and mice deficient in AID are completely
defective in somatic hypermutation [Muramatsu et al., 2000]. Patients diagnosed with an
autosomal recessive form of the hyper-IgM syndrome 2 (HIGM2) revealed that AID
inactivating mutations cause the lack of somatic hypermutation [Revy et al., 2000;
Quartier et al., 2004]. Further, ectopic expression of AID in hybridoma [Martin et al.,
2002], fibroblasts [Yoshikawa et al., 2002], and E.coli [Petersen-Mahrt et al., 2002]
induces hypermutation, suggesting that AID is the only B cell specific trans-acting factor
required for the process. Biochemically, AID deaminates deoxycytidine to deoxyuridine
exclusively in single-stranded (ss), but not in double-stranded DNA; nor in RNA, or
DNA-RNA hybrids [Bransteitter et al., 2003; Pham et al., 2003, Dickerson et al., 2003].
In a cell free in vitro assay, semi-purified AID targeted dC's in the short WRC motif (W
= A or T, R = A or G) preferentially on the non-template DNA strand [Pham et al., 2003;
Chaudhuri et al., 2003; Ramiro et al., 2003; Sohail et al., 2003]. However, in vivo data
show no preference between the transcribed and the non-transcribed strand in mice
[Boursier et al., 2004; Milstein and Neuberger, 1998], and even earlier results show that
purine residues on the coding strand seem to be preferred over pyrimidines as targets for
mutations [Neuberger and Milstein, 1995].
Amino acid (aa) sequence analysis of AID revealed an N-terminal bipartite nuclear
targeting sequence (aa position 9 - 26), but also a nuclear export signal at the C-terminus
(aa position 183 - 198) of the protein [http://au.expasy.org/prosite/]. Mutations in the N-
terminus of AID inactivate somatic hypermutation [Shinkura et al., 2004], whereas
mutations in the C-terminus of AID selectively inactivate Ig-class switch recombination
but retain somatic hypermutation [Barreto et al., 2003; Ta et al., 2003, McBride et al.,
2004].
Class switch recombination is the second mechanism mediated by AID expression in
activated B-cells. This recombination leads to switching in protein expression from IgM
to the other Ig isoforms—IgG, IgE or IgA. AID inactivating mutations were pinpointed
as cause for the name-giving characteristics of the hyper-IgM syndrome 2 in patients: the
lack of other immunoglobulin isoforms [Quartier et al., 2004]. Because induction of class
switch recombination and somatic hypermutation can be assigned to separate domains of
AID, it was hypothesized that specific co-factors might interact with different domains of
AID in order to distinguish the two molecular mechanisms [Shinkura et al., 2004]. Such
co-factors could also account for specific targeting of AID to the V-region during
hypermutation or to the switch regions during switch recombination, respectively.
Secondary modification of AID might be required for specific interaction with co-factors.
The amino acid sequence of AID shows multiple phosphorylation sites at its C-terminus
[http://au.expasy.org/ prosite/], and a phosphorylated form of AID has been reported
[Chaudhuri et al., 2004]. In this paper, it was shown that the non-phosphorylated AID has
no activity in RGYW targeted hypermutation.
Most of the ectopically and endogenously expressed AID is localized in the cytoplasm
[Ito et al., 2004; Rada et al., 2002a]. This fact, together with the high DNA sequence
homology of AID to the apolipoprotein mRNA-editing enzyme catalytic polypeptide 1
(APOBEC-1) led to the notion that AID might edit mRNA rather than ssDNA [Kinoshita
and Honjo, 2001; Honjo, 2002]. Additionally, the requirement for de novo protein
synthesis in the presence of active AID in order to induce somatic hypermutation and
class switch recombination suggested the view that AID does target mRNA [Doi et al.,
2003]. The targeted mRNA would encode the inactive form of the mutator enzyme or
switch recombinase respectively, which would be "activated" by an AID mediated editing
process. But recent accumulation of biochemical data and the finding that AID is actively
exported from the nucleus via the exportin protein CRM-1 pathway [McBride et al.,
2004] led the authors of the mRNA-editing model to abandon it [Honjo et al., 2004].
With AID activating somatic hypermutation by deaminating dC to dU, several
downstream processes have been proposed (Fig. 1). In case the G-U mismatch would
remain through DNA replication, a C→T mutation (or G→A mutation on the opposite
DNA strand) would be produced. This is a mutation pattern which is frequently found
during ectopic AID expression in cell lines and E.coli [Yoshikawa et al., 2002; Sohail et
al., 2003]. Downstream of the AID action, the uracil DNA glycosylase (UNG) plays a
major role in somatic hypermutation by removing the uracil bases. Inhibition of UNG
activity in DT40 cells, and deletion of UNG in AID expressing E.coli, results in an
increase of GC base pair targeted transitions [Di Noia and Neuberger, 2002; Petersen-
Mahrt et al., 2002]. Furthermore, UNG deficiency in mice lead to a perturbed
hypermutation spectrum [Rada et al., 2002b]. However, UNG action leaves an abasic site
(AP site = apurinic or apyrimidimic site), which could have various outcomes depending
on the race between replication and the base excision repair (BER) pathway. In the BER
pathway, the AP-site would be targeted by the AP-endonuclease, which creates a single
strand lesion. The lesion would be repaired by the BER pathway, but without creating
mutations (Fig. 1D). On the other hand, the AP-site could be filled with any base during
translesional replication (Fig. 1B). Another possibility includes the mismatch repair
pathway (MMR), and its involvement in somatic hypermutation has been demonstrated in
several knock out models (Fig. 1C).
Figure 1. Model of somatic hypermutation. During RNA polymerase-mediated transcription (RNAP, orange
oval), AID (yellow oval) and co-factors (blue oval) deaminate cytosines (C) on the single-stranded DNA of
the transcription bubble to generate uracil (U). The result of the reaction is a G-U mismatch, which can be
resolved as follows: A) G-U mismatches remain unaltered, enter DNA replication and result in C→T
mutation. B) UNG removes uracil to generate an abasic site, which can be filled with any base during
replication. C) Mismatch repair (MMR) proteins bind to the G-U base mispairs or G-abasic mismatches and
recruits additional MMR proteins, error prone polymerases and B cell specific subversion factors to generate
and fix mutations. D) UNG removes uracil and the abasic site is processed by base excision repair in an
error free manner. (Model and figure modified after Li et al., 2004 and Neuberger et al., 2003)
1.2.2. Mismatch repair in somatic hypermutation
Misincorporated bases introduced during replication of DNA are repaired by the
postreplicative mismatch repair (MMR) system [Kolodner, 1996]. The eukaryotic MMR
system is mediated by heterodimeric complexes of its bacterial MutL (hMLHs) and MutS
(hMSHs) homologues [Jiricny, 1998; Modrich, 1991]. Depending on the characteristics
of the mismatch, two different complexes initiate the repair process. The hMSH2-hMSH6
(MutSα) complex recognizes single base mismatches, insertions and deletions
[Marsischky et al., 1998], whereas the hMSH2-hMSH3 (MutSβ) complex detects two to
four base pair insertions and deletions [Sia et al., 1997; Alani, 1996; Umar, et al., 1998;
Wei et al., 2002]. Since the recognition of the different classes of mismatches is not
stringent, both MMR complexes share overlapping base mismatch patterns [Genschel et
al., 1998]. The subsequent removal of the base mismatch is promoted by the MutLα
complex, formed by hMLH1 and hPMS2, which interacts with hMSH2 of the MutSα
complex [Plotz et al., 2003]. Although there is reasonable knowledge of the initiation of
the MMR system, less is known about the subsequent excision of the mismatches and
about the proteins involved in the downstream processes. It was suggested that the 3' - 5'
exonuclease 1 (EXO1) is required for MMR in that it presumably stabilizes the MMR
complexes by interacting with hMSH2 and hMLH1 [Genschel et al., 2002; Schmutte et
al., 2001; Amin et al., 2001]. Additionally, FEN1 (RAD27), DNA polymerases δ and ε,
and the DNA replication factors RPA (replication protein A), PCNA (proliferating cell
nuclear antigen) and RFC (replication factor C) might be involved [Kolodner, 1996;
Tischkoff et al., 1997; Amin et al., 2001; Buermeyer et al., 1999]. However, the general
mismatch repair scheme proposes, that after the mismatch has been detected by one of
the various MMR complexes, single stranded nicks would be introduced into the DNA,
which subsequently would be nibbled back and resynthesized by the DNA polymerases
mentioned above.
Loss of MMR leads to a mutator phenotype in both prokaryotic and eukaryotic cells. In
humans, loss of MMR ultimately results in microsatellite instability, which is frequently
found in tumors of patients diagnosed with hereditary nonpolyposis colorectal cancer
(HNPCC) [Bronner et al., 1994]. Cancer predisposition is linked to germline mutations in
MMR genes and most mutations associated with HNPCC were found in hMLH1,
hMSH2, and hMSH6 genes [Peltomaki and Vasen, 1997]. Mutations in hPMS2 were
reported sporadically. The majority of all HNPCC causing mutations were found in
hMLH1 (61%), making the analysis of pathogenic hMLH1 variants a proprietary goal
[Trojan et al., 2002]. Interestingly, loss of EXO1, FEN1 and PCNA function results in a
mutator phenotype, but does not seem to significantly contribute to HNPCC formation
[Kolodner, 1996].
In contrast to the increased levels of spontaneous mutations in MMR deficient cell lines
and mice, somatic hypermutation frequencies decrease in activated B cells of MLH1 or
PMS2 deficient mice [Cascalho et al., 1998; Phung et al., 1999]. Mutation frequencies do
not seem to be decreased in MSH2 deficient mice [Phung et al., 1998]. It has been
suggested that AID would introduce the G-U mismatch, which would be detected by the
mismatch repair system. Ultimately this would lead to several single stranded nicks in the
DNA backbone, which could result, if positioned in close proximity, in double strand
breaks. The findings of double and single strand breaks in V(D)J regions during somatic
hypermutation support this theory [Papavisiliou and Schatz, 2000; Bross et al., 2000;
Kong and Maizels, 2001]. After introducing the nick into the DNA segment, it would be
nibbled back, resynthesized, and repaired as postulated for repair of damaged DNA. Error
prone polymerases, such as polymerase η, ζ, and ι would then introduce mutations during
the resynthesis step [Diaz et al., 2001; Poltoratsky et al., 2001; Rogozin et al., 2001;
Zeng et al., 2001]. However, there is a difference between "normal" DNA repair and the
resynthesis of a hypermutated DNA: the mutations need to get fixed, not eliminated. We
suggest a subversion factor, which would interact with DNA repair factors, such as pms2,
mlh1, or msh2. A general model for how this would occur has been suggested by
Cascalho et al. [Cascalho et al., 1998] (Fig. 2). Here, the newly synthesized DNA strand
rather than the pre-existing one, is used as a repair template and the mismatches would be
corrected in the reverse (Fig. 2B). In another suggested mechanism, epigenetic marks,
which distinguish parental from newly synthesized strands, are removed and mismatch
repair would choose randomly between the two strands for its template (Fig. 2D). In this
case, a base substitution stands a 50:50 chance of being immortalized. Yet another
suggestion involves homologous DNA repair [Papavasiliou and Schatz, 2000].
However, contradicting mutation rates have been calculated in MMR knock out mice
models, and this may depend on the approach used to measure mutation rates in those
models [Frey et al., 1998; Jacobs et al., 1998; Rada et al., 1998]. In these studies, a
comparison of DNA sequences with wild type sequences or germline sequences build the
basis for conclusions. Frequently, MMR deficient mice were injected with a particular
antigen and antigen specific B-cells were collected after several rounds of antigen boosts
[Frey et al., 1998; Phung et al., 1999; Kim et al., 1999]. Alternatively, memory B-cells
from peripheral blood samples of non-immunized mice were analyzed.
Figure 2. General model of fixing mismatches during somatic hypermutation. A) Normal postreplicative
mismatch repair (MMR) in which the parental DNA strand serves as template to eliminate the mutation. B)
Backward repair during somatic hypermutation: The newly synthesized DNA strand serves as template and
MMR fixes the mutation in the parental strand. C) Mutation activation genes (MAG) introduce mutations in
the parental DNA strand during somatic hypermutation, which would remain undetected and would be fixed
in the newly synthesized DNA strand. D) Epigenetic marker loss causes undifferentiated integration of
mutations by mutation activation genes (MAG) in the parental and newly synthesized DNA strand. MMR
fixes mutations with a 50:50 chance in one of the DNA strands depending on which strand would serve as
repair template. (modified after Shannon and Weigert, 1998)
This approach should reduce the selection pressure towards the antigen and the antibody
specifies analyzed should represent their "natural" antigen environment [Cascalho et al.,
1998]. Subsequently, selected V-regions were amplified by PCR and the products were
sequenced. Frey et al. [Frey et al., 1998] and others [Jacobs et al., 1998; Phung et al.,
1998] found no difference in mutation frequencies between MSH2-deficient mice and
wild type mice when they analyzed splenic germinal center cells. But when the same
groups analyzed Peyer's patch germinal center B cells from the same mice, they observed
a significant reduction in mutation frequencies [Frey et al., 1998; Phung et al., 1998]. It
can thus be concluded that in order to study the influence of mismatch repair proteins in
somatic hypermutation, a system without selection pressure by antigen would be
desirable.
In addition to the altered mutation frequencies, mutational patterns seem to differ
depending on the MMR protein that is knocked out. MSH2 or MSH6 knock out mice
show the majority of mutations in GC base pairs embedded in the WRCY motif, leading
to G→A or C→T transitions [Phung et al., 1998; Rada et al., 1998]. Whereas mice
deficient in MLH1 or PMS2 do not exhibit dramatic alterations in their mutation spectra,
but still reveal decreased mutation rates [Cascalho et al., 1998; Phung et al., 1999].
1.3. Mutation rates measurements
As already mentioned, most of the MMR data in somatic hypermutation were
accumulated in knock out mouse models where selection pressure towards the antigen
will influence the read out of mutation frequencies and mutation patterns. However,
generally one has to consider what classic population genetics taught about mutation
frequencies [Wabl et al., 1987]. Factors like mutation, selection, migration, drift and
recombination influence the frequency of an allele in a population. Especially for in vivo
experiments the "selection" factor influences the read out, since clonal selection is the
basic fact of the immune system. Immunizing mice drives the clonal selection process
and it seems obvious that mutation frequencies and mutation patterns depend on the
nature of the antigen, the application form and entrance way of the antigen, the B cell
type analyzed and the tissue environment B cells were taken from. Further, the distinct
definition between "mutation frequency" and "mutation rate" needs to remain clear. A
high mutation frequency does not necessarily result in a high mutation rate as shown by
Wabl et al. [Wabl et al., 1987].
Taking these issues into consideration, the in vitro compartmentalization test offers the
opportunity to avoid the influence of selection, migration, and drift in cell culture
experiments [von Borstel et al., 1971]. The original compartmentalization test (P0
method) by Luria and Delbrück depends on a majority of clones that do not contain any
mutants [Luria and Delbrück, 1943]. Because one needs to estimate the average number
of mutational events per clone, high numbers of individual clones need to be included per
experiment—a time-consuming undertaking [Wabl et al., 1987]. An experimental
solution to the so-called Luria-Delbrück fluctuation problem in somatic hypermutation
was first achieved by Bachl et al. [Bachl et al., 1999]. Here a hypermutating cell line was
stably transfected with an indicator plasmid, which contained all cis-acting elements to
target the mutator. Mutator action was detected by the reversion of an amber stop codon
embedded in the RGYW hot spot motif for somatic hypermutation in a green
fluorescence protein gene (GFP). Based on one clone, a sizable cell population was
grown up and then purged from pre-existing revertants by fluorescence activated cell
sorter (FACS). Sorted cells were taken back into culture and expanded for some time. As
a result, the number of revertants increased linearly with time. Even though this method
could avoid the Luria-Delbrück fluctuation effect, it still had to deal with certain
limitations of positional effects of the transfected reporter.
1.4. Specific Aims
For this thesis, I had three specific aims: (1) Develop a retroviral based point mutation
indicator system. (2) Characterize the IgH major intronic enhancer and other enhancer
elements, as cis-elements in hypermutation. And (3) Mismatch repair in somatic
hypermutation in non-B cells.
1.4.1. Specific Aim 1: Develop a retroviral based point mutation indicator system
To measure mutation rates fast and reliably, I set out to develop a retroviral indicator
system for hypermutation that can be used in cell lines and would monitor mutation rates
and transcription rates simultaneously. Furthermore, mutator activity should be easily
detected by flow cytometry. Because retroviruses are able to infect high numbers of cells,
and because the retroviral constructs integrate at different sites of the host cell genome, a
position effect is less likely than for low numbers of stable transfectants. Further,
working with high numbers of infected cells avoids time and material consuming
compartmentalization tests, which are necessary when events follow a Poisson
distribution; instead, a normal (Gauss) distribution can be expected. Finally, working
with bulk cultures avoids time consuming single cell subcloning.
1.4.2. Specific Aim 2: Characterize the IgH major intronic enhancer and other
enhancer elements, as cis-elements in hypermutation
With a mutation indictor system in hand that allows to simultaneously monitor
transcription rates and mutation rates, the plan was to study the role of cis-acting
elements in targeting somatic hypermutation. Because it is known that hypermutation
rates correlate with transcription rates, I set out to study the ability of various
immunoglobulin and other enhancer elements to target the mutator complex to the
indicator gene; and their function as transriptional enhancers. This would be done by
placing enhancer elements at various locations within the reporter construct.
1.4.3. Specific Aim 3: Mismatch repair in somatic hypermutation in non-B cells
MMR deficiency leads to a substantial reduction of the mutation rate in the V-region of
hypermutating B cells. Consequently, we hypothesized that the mismatch repair system is
co-opted in hypermutating B cells, and that it actively fixes base mismatches in V regions
rather than repairing them. Since fixing mismatches needs to be restricted to activated B
cells, it was suggested that one or more B cell specific factors would be involved in the
process. However, in non-B cells, the loss of MMR should increase the mutation rate, or,
if it is very high, not influence it at all. I set out to test these assumptions in a kidney cell
line, which allows regulated expression of the mismatch repair protein MLH1. Mutation
frequencies would be measured by using retroviral point mutation indicator vectors in the
presence and absence of MMR.
2. Materials and Methods
2.1. Materials
2.1.1. Instruments
Centrifuge: Sorvall RC-5C, rotor: GSA, SS34 [Sorvall, Wilmington, CA]
TechnoSpin R, rotor: microplate carrier [Sorvall, Wilmington, CA]
PCR-machines: PTC-100 Peltier Thermal Cycler [MJ Research, Watertown, MA]
PTC-200 Peltier Thermal Cycler [MJ Research, Watertown, MA]
Gel-electrophoreses: Hoefer Scientific instruments [Hoefer Sci., San Francisco, CA]
Photo documentation: UV-lamp: Prep I, Fotodyne [Fotodyne, Foster City, CA]
Camera: Fotodyne and Polaroid film
Spectrophotometer:  Spectronic 601 [Bausch and Lomb, San Clemente, CA]
Culture-shaker: Innova 4000 [New Brunswick scientific, Princton, NJ]
C24 [New Brunswick scientific, Princton, NJ]
Incubator: VWR 1530 [VWR Scientific Inc., Hayward, CA]
Isotemp 500 [Fisher Scientific, San Francisco, CA]
IS-61 [American Scientific, La Jola, CA]
Cell culture-incubator: B5060-EK-CO2 [Haeraeus, Diagnostic Product Corporation,
 San Francisco, CA]
pH-meter: pHI-Meter [Beckmann, Diagnostic Product Corporation, San
Francisco, CA]
FACS MoFlow [Cytomation, Fort Collins, CL]
FACS Vantage [Becton Dickinson, Fremont, CA]
2.1.2. Enzymes and reaction kits
All restriction enzymes were obtained from New England Biolabs [New England
Biolabs, Beverly, MA]. Taq- and Pfu-DNA polymerases were obtained from Invitrogen
[Invitrogen, Carlsbad, CA].
The following reaction kits were used for this thesis:
Kit type Maker
Plasmid isolation kits:
QIAprep spin Miniprep kit
QIAfilter Plasmid Maxi kit
QIAEX II gel extraction kit
Oligotex mRNA Mini kit
DNeasy Tissue kit
SuperScript III RNase H- RT
QuickChangeSite-Directed Mutagenesis
Qiagen, Valencia, CA
Qiagen, Valencia, CA
Qiagen, Valencia, CA
Qiagen, Valencia, CA
Invitrogen, Carlsbad, CA
Stratagene, La Jolla, CA
2.1.3. Antibodies and enzyme conjugated anti-antibodies
AID of human or mouse origin was detected with a polyclonal rabbit anti-AID antibody,
which was a kind gift of F. W. Alt [Chaudhuri et al., 2003]. AID antibodies were
detected in western blots with goat anti-rabbit IgG (H+L)-HRP (human and mouse
adsorbed) antibodies [Southern Biotechnology Associates Inc., Birmingham, AL]. To
detect human MLH1, monoclonal mouse anti-human MLH1 antibody [BD Pharmingen,
San Jose, CA] was used, followed by HRP-conjugated goat anti-mouse IgG (H+L)
polyclonal antibody [Southern Biotechnology Associates Inc., Birmingham, AL]. A
polyclonal rabbit anti-mouse actin serum [Oncogene Research Products, San Diego, CA]
was used to detect mouse actin in loading controls. The anti-actin Ab was detected with a
goat anti-rabbit IgG Ab coupled to HRP [Southern Biotechnology Associates Inc.,
Birmingham, AL].
2.1.4. Bacterial strains
In cloning strategies and for plasmid storage, E.coli TOP10 cells [Invitrogen, Carlsbad,
CA] were used. As a recipient for recombinant DNA modified by site directed
mutagenesis with the Qiaquick Change kit, Epicurian coli XL 1-Blue supercompetent
cells were used [Stratagene, La Jolla, CA; Bullock et al., 1987].
E.coli strain Genotype
Top10
Epicurian coli XL
1-Blue
F- mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacX74 recA1
deoR araD139 ∆(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG
RecA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F' proAB
laclqZ∆M15 Tn10 (Tet')]
2.1.5. Plasmid and retroviral vector construction
To create pLNCX2-eGFP, the GFP gene of pEGFP-NI [Clontech, San Jose, CA] was
excised from the XhoI and NotI restriction sites and placed into the according restriction
sites of pLNCX2 [Clontech, San Jose, CA; figure 4]. The coding sequence of activation
induced cytidine deaminase (AID) was reverse transcribed from mRNA of the murine 18-
81 pre B-cell line, which expresses AID constitutively [Wabl et al., 1985; Bachl et al.,
2001]. For specific amplification of AID from cDNA the primer set AID-fwd and AID-
back was used [2.1.5]. The PCR product was cloned into the pCR2.1-TOPO plasmid
[Stratagen, La Jolla, CA] before it was transferred into the HindIII and NotI site of the
retroviral pLNCX2 vector to create pLNCX2-mAID.
All mutation indicator plasmids were based on the retroviral CRU5-IRES-eGFP vector
(102.IG) [J.B. Lorens, unpublished, figure 4], which is derived from the p96-dsG plasmid
[Lorens et al., 2000].
CRU5-YFP-IRES-GFP vectors. To create the CRU5-YFP (102.Y) single color positive
control, the eYFP coding sequence of the pEYFP plasmid [Clontech, San Jose, CA]
replaced the IRES-GFP fragment between the XhoI and NotI restriction sites in 102.IG.
The 102.Y-IG two-color positive control vector was created by first amplifying the eYFP
gene from pEYFP using the YFP-XhoI and the YFP-BstXI primer [2.1.5]. The PCR
product was introduced into the 102.IG vector via the XhoI and BstXI restriction sites. To
prepare the point mutation indicator gene, an amber stop-codon was introduced at base
pair 321 into the eYFP coding sequence by site directed mutagenesis using the
QuickChangeSite-Directed Mutagenesis kit with the YFP-stop oligomere [2.1.5].
Plasmid pEYFP served as template for the reaction and the created sequence was
designated Y(X). Y(X) was PCR amplified using the YFP-XhoI and YFP-BstXI primer
set and introduced into the XhoI and BstXI restriction sites of 102.IG to create the
102.Y(X)-IG vector.
CRU5-DsRed-IRES-GFP constructs. In our cloning strategy to make point mutation
indicator plasmids, we mutated the serine codon UCC at aa position 179 to a UCA codon
which also encoded for serine, in the DsRed2 gene [Klasen and Wabl, 2004]. This silent
point mutation destroyed the BstXI restriction site in the DsRed2 gene. To obtain this
mutant, pDsRed2-1 served as PCR template for site directed PCR mutagenesis using the
DsRed-mut 537 oligomer [2.1.5] and the QuickChangeSite-Directed Mutagenesis kit.
A.
B.
Figure 3. Plasmid maps of (A) pLNCX2 [Clontech, San Jose, CA] and (B) 102.21 (CRU5-IRES-eGFP) [J.B.
Lorens, Rigel Inc., San Francisco, CA]. CRU5 = composite minimal CMV and MoMuLV 5'LTR promoter
fusion, ψ = (extended) packaging signal, IRES = internal ribosome binding site, eGFP = enhanced green
fluorescence protein, CMV IE = full size immediate early CMV promoter, Neor = neomycin resistance gene,
LTR  = long terminal repeat
Because the procedure replaced the cytidine by an adenosine at nucleotide position 537,
we designated the mutated gene DsRed537. The sequence of the mutated gene was
verified before and after cloning into mammalian vectors. The mutated and original
DsRed genes were cloned into the XhoI and NotI restriction sites of the CRU5-IRES-
GFP, replacing the IRES-GFP fragment. This way plasmids CRU5-DsRed2 (102.R) and
CRU5-DsRed537 (102.Rm) were created. The same strategy was used to mutate and
clone the DsRed-Express1 gene based on the pDsRed-Express1 vector [BD Biosciences
Clontech, Palo Alto, CA] to create CRU5-DsRed-Express1 (102. REx) and CRU5-Red-
Express537 (102. RExm) [Klasen and Wabl, 2004]. Replacing the IRES-GFP fragment
between the XhoI and NotI site of 102.IG with the HcRed coding sequence from
pHcRed1-N 1/1 [Clontech, San Jose, CA] created the plasmid CRU5-HcRed (102.Hc).
However, the DsRed537 coding sequence was PCR amplified using the Red-XhoI 5'
primer and the Red-BstXI 3' primer [2.1.5]. The PCR fragment contained a 5' XhoI and a
3' BstXI restriction site and was placed upstream of the IRES element into 102.IG to
create 102.Rm-IG (CRU5-Red537-IRES-eGFP). An amber stop-codon was introduced
into the DsRed537 coding sequence at nucleotide position 519 by site directed PCR
mutatgenesis using the Red-stop oligomere [2.1.5]. The resulting gene was designated
Rm(X), which was PCR amplified using the primer pair Red-XhoI 5' and Red-BstXI 3'.
The PCR product replaced the DsRed537 sequence in 102.Rm-IG to create the
102.Rm(X)-IG vector.
The 1 kb Eµ intronic enhancer was PCR amplified from the pµ plasmid [Grosschedl et
al., 1984] using the oligomeres Emu - BstXI 5' and Emu - BstXI 3' [2.1.5]. The 721 bp
fragment of the kappa intronic enhancer (κi) was PCR amplified from the pAkv-κi vector
[C.L. Wang, personal communications; Klix et al., 1998] using the oligomeres κi - BstXI
5' and κi - BstXI 3'. The 236 bp SV40 enhancer was amplified from the pGL3-enhancer
plasmid [Stratagene, La Jolla, CA] using the oligomeres SV40 COR 5' and SV40 COR 3'
[2.1.5]. The 808 bp comprising kappa 3' enhancer (κ3') [Max et al., 1981] was PCR
amplified from chromosomal DNA of the 18-81 cell line using the primers Kappa BstXI
5' and Kappa BstXI 3'. All enhancer PCR fragments contained a BstXI restriction site on
the 5' and 3' end and were placed into the BstXI site of the 102.Rm-IG or 102.Rm(X)-IG
vector, respectively. To create the 102.Rm(X)-IG-Eµ vector the Eµ enhancer was
amplified with Eµ-NotI forw and Eµ-NotI back oligomeres [2.1.5] and placed into the
NotI restriction site of the 102.Rm(X)-IG plasmid.
When the GFP gene was used as point mutation indicator gene in the CRU5-IRES-GFP
vector, the amber stop-codon was introduced at base pair 321 into the GFP gene. The
102.IG plasmid served as template for the site directed mutagenesis reaction using the
YFP-stop oligomere to introduce the stop-codon, which generated the 102.IG(X) vector.
Using the cloning strategy previously mentioned, the DsRed537 gene was introduced into
102.IG(X) between the XhoI and BstXI restriction site to create 102.Rm-IG(X). The Eµ
enhancer was introduced into the 102.Rm-IG(X) construct as described above via the
NotI site positioned downstream of the GFP gene. This engineering step resulted in the
102.Rm-IG(X)-Eµ plasmid.
The vectors pGFP-Ipuro (CRU5-GFP-IRES-Puromycinr), pGFP*-Ipuro and pGFP*-Emu-
Ipuro were kind gifts of C. L. Wang [Wang et al., 2004]. To create the vectors 102.Rm-
IN (CRU5-DsRed537-IRES-Neomycinr) and 102.Rm(X)-IN, the IRES-GFP fragment of
the corresponding 102.Rm-IG vectors was replaced with the IRES-Neomycin fragment
between the EcoRI  and NheI restriction sites of the pBMN-Z-I-Neo vector [kindly
provided by Gary P. Nolan, Stanford University School of Medicine, Stanford, CA.
Plasmid engineering by F.J.X. Spillmann, personal communications]. All constructs were
verified by DNA sequencing.
2.1.6. Oligonucleotides
Cloning primers
AID-fwd
5'- CGC CCA TGG TGG TGG GCC ACC ATG GAC AGC CTT CTG ATG -3'
AID-back
5'- ATG GTT CCA ATT TAA TGG TCA AAA TCC CAA CAT ACG AAA TGC -3'
YFP-XhoI primer
Ov            (XhoI site) annealing region
5'- TTA AG (CTC GAG) GCT CTA GAA CTA GTG GAT CCC CGC G -3'
YFP-BstXI primer
Ov          (BstXI site b) annealing region
5'- TA (CCA ATT TAA TGG) TTA CTT GTA CAG CTC GTC CAT GCC -3'
YFP-stop oligomer
5'- TCG GCG CGG GTC TGC TAG TTG CCG TCG TCC TT -3'
DsRed-mut 537 oligomere
5'- TGG TGG AGT TCA AGT CAA TCT ACA TGG CCA AGA AGC C -3'
Red-XhoI 5' primer
Ov     (XhoI) annealing region
5'- AA (CTC GAG) CGC CAC CAT GGC CTC CTC CG -3'
Red-BstXI 3' primer
Ov       (BstXI site b) annealing region
5'- AA (CCA ATT TAA TGG) CTA CAG GAA CAG GTG GTG GCG G -3'
Red-stop oligomer
5'- GAC GGC GGC CAC TAG CTG GTG GAG TTC AAG -3'
Emu - BstXI 5'
Ov        (BstXI site b) annealing region
5'- TT (CCA TTA AAT TGG) TCT AGA GAG GTC TGG TGG AG -3'
Emu - BstXI 3'
Ov        (BstXI site b)  annealing region
5'- TA (CCA ATT TAA TGG) TCT AGA TAA TTG CAT TCA TTT AAA AAA A -3'
κi - BstXI 5'
Ov    (BstXI site b) annealing region
5'- TT ACG (CCA TTA AAT TGG) AGC TCA AAC CAG CTT AGG C -3'
κi - BstXI 3'
Ov       (BstXI site b) annealing region
5'- ATG GTT (CCA ATT TAA TGG) CTA GAA CGT GTC TGG GCC -3'
SV40 COR 5'
Ov       (BstXI site b) annealing region
5'- TT ACG (CCA TTA AAT TGG) CGA TGG AGC GGA GAA TG -3'
SV40 COR 3'
Ov        (BstXI site b) annealing region
5'- TG GTT (CCA ATT TAA TGG) GCT GTG GAA TGT GTG TC -3'
Kappa BstXI 5'
Ov     (BstXI site b) annealing region
5'- TT ACG (CCA TTA AAT TGG) AGC TTA ATG TAT ATA ATC TTT TAG -3'
Kappa BstXI 3'
Ov      (BstXI site b) annealing region
5'- ATG GTT (CCA ATT TAA TGG) GGT GTC CAG AAA TAT TCT G -3'
Eµ - NotI forw.
Ov (NotI) annealing region
5'- AAT (GC GGCC GC) TCT AGA GAG GTC TGG TGG AG -3'
Eµ - NotI back.
Ov (NotI) annealing region
5'- AAT  (GC GGCC GC) TCT AGA TAA TTG CAT TCA TTT AAA AAA A -3'
Sequencing primers
102. MCS-5'
5'- GAT CTC GAG GGA TCC ACC ACC ATG G -3'
IRES-back
5'- CGC TCT AGA ACT AGT GG -3'
pLNCX2 seq5'
5'- AGC TCG TTT AGT GAA CCG TCA GAT C -3'
pLNCX2 seq3'
5'- ACC TAC AGG TGG GGT CTT TCA TTC CC -3'
2.2. Cell culture based methods
2.2.1. Mammalian cell lines and cell culture conditions
Murine 18-81 lymphocyte cell line [Wabl et al., 1984]. The 18-81 pre B-cell line
continuously hypermutates in culture. Because its light chain locus is not rearranged and
a pre B-cell receptor is not expressed on the cell surface, the cell line is considered to be a
pre B-cell line. To obtain this cell line, murine pre B-cells were transformed with the v-
abelson virus. In this thesis the 18-81.10-17.93 sublone was used and cultured in RPMI
1680 medium supplemented with 10% (v/v) fetal bovine serum (FBS), 2 mM L-
glutamine, 1 mM sodium pyruvate, 50 IU/mL penicillin-streptomycin, and 50 mM β-
mercaptoethanol. At a temperature of 37°C and 5% CO2 cells divided three times in 24
hours.
Murine 70Z/3 pre B-cell line. The 70Z/3 cell line is a hypermutation inactive pre B-cell
line and was cultured under the same conditions like the 18-81 line.
Phoenix eco- and amphotropic cell line [Swift et al., 1999]. The Phoenix E and
Phoenix A cell line was a kind gift of Gary P. Nolan [Stanford University School of
Medicin, Department of Pharmacology, Stanford, CA]. Both cell lines are based on the
human kidney cell line 293T and carry the MuMoLV packaging genes
[http://www.stanford.edu/group/nolan/]. The Phoenix cell line was cultured in DMEM
medium containing 10% (v/v) FBS (heat inactivated), 4 mM L-glutamine and 50 IU/mL
penicillin-streptomycin at 10% CO2 and 37°C.
Murine NIH/3T3 fibroblast cell line ATCC CRL-1658. The NIH/3T3 cell line was
obtained from ATCC [www.atcc.org] and was cultured like Phoenix cells.
Human embryonic 293T-Tet-Off-hMLH1 kidney cell line. The human 293T-Tet-Off-
hMLH1 cell line was maintained in culture as characterized by Trojan et al. [Trojan et
al., 2002]. Briefly, cells were cultured at 37ºC and 10% CO2 in DMEM medium
supplemented with 4 mM L-glutamine, 100 U/ml penicillin-streptomycin, 10% Tet-
system approved FCS [Clontech, San Jose, CA], 300 µg/ml hygromycin B [Roche
Applied Science, Indianapolis, IN], and 100 µg/ml Zeocin [Invitrogen, Carlsbad, CA].
Tet-response element controlled hMLH1 expression was inhibited with 50 ng/ml
doxycyclin [BD Biosciences Clontech, Palo Alto, CA].
2.2.2. Cryostorage of cell lines
18-81, 70Z/3, and NIH/3T3 cells were frozen in their complete culture medium, which
was supplemented with 5% (v/v) DMSO. 2 x 107 cells were frozen in 800 µl freezing
medium in a cryotube [Nunc, Rochester, NY]. Phoenix cells were frozen in 90% FCS
(heat inactivated) containing 10% (v/v) DMSO. 5 x 106 cells were frozen in a volume of
800 µl freezing medium. All cell lines were stored in liquid Nitrogen Cryotank at -140ºF.
2.2.3. Rapid production of retroviruses in Phoenix cells [Swift et al., 1999].
This method is applicable to both the ecotropic and the amphotropic Phoenix packaging
cell line.
Preparation and transfection of Phoenix packaging cells. 24 hours prior transfection,
2 x 105 Phoenix cells were seeded into one 6 cm well of a Falcon multiwell plate [Becton
Dickinson, New Jersey, NY]. Transfections were performed with 3 µl FuGENE6
reagent [Roche Applied Science, Indianapolis, IN] and 1 µg retroviral plasmid DNA
(Qiagen maxiprep quality) according to the manufacture's manual. Depending on the
target cell line, 24 hours after transfection the medium was changed to the medium
conditions of the cell line to transduce. On average, Phoenix cells produced a virus titer
of 5 x 105 infectious virus particles per ml (IVP/ml) after 48 hours of incubation at 37°C
and 5% or 10% CO2 [Pear et al., 1993]. Optional cells were transferred to a 32°C
incubator, which slowed down cell division without significantly decreasing virus
production. This temperature has been suggested to increase the stability of retroviral
particles [Kotani et al., 1994].
2.2.4. Spin infection of adherent cells
Twelve to sixteen hours prior infection, adherent cells (e.g. NIH/3T3 cells) were
trypsinized and 5 x 105 cells were transferred into one 6 cm well of a Falcon multiwell
plate [Becton Dickinson, New Jersey, NY]. To infect target cells, the culture medium of
the target cells was removed and the retrovirus containing supernatant from one 6 cm
well of transiently transfected Phoenix E cells was added by filtering it through a 0.45
µm surfactant free cellulose acetate membrane filter [Nalgene, New York, NY]. 4 µg/ml
Polybrene (hexadimethrine bromide) [Sigma, St. Louis, MO] were added to the
supernatant and the 6 well plates were sealed with parafilm. Plates were centrifuged at
1200 x g for 60 min at RT on a microplate carrier [Sorvall, Wilmington, CA]. After
centrifugation, parafilm was removed and cells were placed in a 37°C incubator over
night. The next morning, the culture supernatant was replaced by fresh complete medium
according to the culture conditions of the target cell line.
2.2.5. Spin infection of suspension cells
To infect 1 x 106 exponentially growing target cells (e.g. 18-81), they were transferred
into one 6 cm well of a Falcon multiwell plate [Becton Dickinson, New Jersey, NY].
Cells were centrifuged on a microplate carrier [Sorvall, Wilmington, CA] at 1200 x g for
5 min at RT. After centrifugation, the supernatant of the target cells was carefully
removed. The retroviral supernatant from three samples was pooled and filtered through a
0.45 µm surfactant free cellulose acetate membrane filter [Nalgene, New York, NY]. The
retroviral supernatant was added to the target cells and supplemented with 4 µg/ml
Polybrene (hexadimethrine bromide) [Sigma, St. Louis, MO]. The plates were sealed
with parafilm and centrifuged on a microplate carrier at 1200 x g for 60 min at RT. After
centrifugation, the parafilm was removed and cells were placed in a 37°C incubator over
night. The next morning, the cells were centrifuged and the cell pellet was resuspended in
fresh complete medium according to the culture conditions of the target cell line.
2.2.6. Fluorescent adsorbent cell sorting (FACS)
High speed cell sorting was performed either on a MoFlow (Cytomation, Fort Collins,
CL) or a FACS Vantage (Becton Dickinson, Fremont, CA). In preparation to a FACS,
adherent cells were trypsinized and concentrated by centrifugation (1200 x g, 5 min,
4°C). The cells were resuspended in approximately 1 ml of serum free medium and
filtered through a 0.45 µm cell separator [BD Falcon, BD Biosciences, Bedford, MA].
Except for trypsinizing, suspension cells were prepared the same way. Until sorting, cells
were kept on ice. The cells were sorted into FBS or complete culture medium
supplemented with 1 mM HEPES buffer. After sorting, cells were washed twice with
complete culture medium.
FACS settings. To achieve a separation of the GFP signal from the YFP signal during
FACS, a 488 nm exitation wavelength at 200 mW was applied. Light passed a 555 long
pass beam splitter before the GFP signal in channel 1 passed a 510/20 short pass filter in
combination with a 530/30 short pass filter for YFP in channel 2. The DsRed signal was
separated form the GFP signal by applying a 530/30 short pass filter in FL1 for GFP and
a 580/30 short pass filter for DsRed in FL2. HcRed exitiation required a separate 568 nm
laser line at 200 mW in combination with a 640 nm long pass filter in the FL2 channel.
2.2.8. Analytical flow cytometry
For analytical flow cytometry, cells were prepared similar to that for a FACS. The
analytical flow cytometry was performed on a FACS Calibur [BD Bioscience, San
Jose, CA].
2.3. Molecularbiological Methods
2.3.1. Strain maintenance and strain conservation
E.coli strains were maintained on Luria broth (LB) agar plates, which were supplemented
with the appropriate antibiotics for plasmid selection. The plates were stored up to three
weeks at 4°C, before the E.coli strains were transferred on fresh LB agar plates.
Cryo-conservation of E.coli strains. For this procedure, 400 µl of a fresh E.coli
suspension culture were mixed with 200 µl of 50% (v/v) glycerol (sterile), transferred
into a cryo-tube [Nunc, Rochester, NY], and frozen at - 80°C.
2.3.2. Making chemically competent E.coli cells (RbCl method by Hanahan)
Ready-to-use competent E.coli Top10 cells were purchased from Invitrogen [Invitrogen,
Carlsbad, CA] and used according to the manufacturer's manual. Self-made chemically
competent E.coli cells were produced as described by Hanahan [Hanahan, 1976].
2.3.3. Heath shock transformation of competent E.coli cells
Commercially available E.coli Top10 cells were transformed according to the
manufacture's manual [Invitrogen, Carlsbad, CA]. Self made E. coli cells were thawed on
ice. Up to 50 ng plasmid DNA were carefully mixed with the competent cells and
incubated for 30 min on ice. To heat shock the cells, the sample was incubated for 1 min
at 42°C in a water bath. Afterwards, the cells were immediately chilled for at least 2 min
on ice. To regenerate the antibiotic resistance encoded by the plasmid, 400 µl SOC
medium [Sambrook et al., 1989] were added to the cells, followed by an incubation step
of 1 hour at 37°C at 200 rpm. Up to 200 µl of the cell suspension were inoculated on a
LB agar plate supplemented with the appropriate antibiotics and incubated over night at
37°C.
2.3.4. Purification of plasmid DNA
For standard cloning procedures, plasmid DNA was purified from E.coli cells of a 5 ml
over-night culture according to the Qiaprep Mini plasmid purification protocol [Qiagen,
Valencia, CA]. Cell culture grade plasmid DNA, i.e. for transfection experiments, was
obtained by using the Qiaprep Midi- or Maxi- plasmid purification kit [Qiagen, Valencia,
CA].
2.3.5. Isolation of chromosomal DNA from mammalian cells
Chromosomal DNA was isolated from 5 x 106 cultured cells using the DNAeasy
chromosomal DNA isolation kit [Qiagen, Valencia, CA] according to the manufactures
manual.
2.3.6. Isolation of polyA+  mRNA
The isolation of polyA+ mRNA was performed according to the Oligotex mRNA Mini
kit protocol [Qiagen, Valencia, CA].
2.3.7. Preparative and analytical gel electrophoresis
DNA fragments were separated in 0.8% - 2% agarose gels containing ethidium bromide
as described by Sambrook et al., [Sambrook et al., 1989]. DNA bands were visualized on
an UV-transluminator at a wavelength of 360 nm. In case of a preparative gel
electrophoresis, the DNA fragment of choice was cut out of the gel using a scalpel and
DNA was subsequently extracted from the gel using the Qiaex II gel extraction kit
according to the manufacturer [Qiagen, Valencia, CA].
2.3.8. Concentration measurements and purity estimations of plasmid DNA
The DNA concentration of plasmid preparations was measured in agarose gels after
electrophoresis at a wavelength of 360 nm. The fluorescence intensity of the sample band
was compared with the fluorescence intensity of a band of known DNA content from
either the High DNA Mass Ladder [Invitrogen, Carlsbad, CA] or the Low DNA Mass
Ladder [Invitrogen, Carlsbad, CA] [Sambrook et al., 1989]. The purity of DNA was
estimated spectrophotometrically in quartz cuvettes by calculating the extinction ratio of
the DNA at 260 nm and 280 nm [Müller et al., 1993].
2.3.9. Endonuclear restriction digest of DNA
DNA restriction digests were performed according to the guidelines of the restriction
enzyme manufacturer. In compliance with time and temperature optima, 2 - 5 units of
restriction enzyme were used per 1 µg DNA.
2.3.10. DNA-Ligation
In preparation for a DNA ligation, digested DNA fragments (insert) and vector DNA
were purified using the Qiaex II gel extraction kit and the DNA concentration was
measured on an agarose gel. Two different kinds of ligations were performed. In a so-
called "sticky end" ligation, two DNA fragments with complementary ends were joined.
In a "blunt-end" ligation two DNA fragments with straight ends were combined. The
phosphodiester bridge between the DNA fragments was built by the T4 DNA-ligase
[Qiagen, Valencia, CA], which was used according to the manufactures instructions. In
general, a 3:1 molar ratio of "insert"- to vector - DNA was used in a sticky end ligation.
For blunt end ligations an insert to vector ratio of 5:1 was used. After ligation, competent
E.coli cells were transformed with the reaction product.
2.3.11. PCR amplification of DNA fragments
Polymerase chain reactions [Saiki et al., 1985] were carried out in 200 µl OPS thin wall
PCR tubes [Online products for science, Petaluma, CA; www.op4s.com]. A standard
PCR contained:
0.01 - 10 ng template DNA
10 pmol primer 1
10 pmol primer 2
1.5 mM MgCl2
0.2 mM/dNTP dNTP-mix (1.25 mM/dNTP)
10% (v/v) 10x Taq DNA polymerase buffer
1 U Taq DNA polymerase
ad 50 µl ddH2O
Amplifications were performed in Peltier Thermal Cyclers PTC-100 or PTC 200 [MJ
Research, Watertown, MA]. Amplification profiles altered with application, but a
standard program contained the following steps:
Denaturation of template DNA 94°C / 60 sec
Primer annealing    variable°C / 60 sec
Extension 72°C / 60 sec per 1 kb DNA length
In general, the three program steps were repeated 30 times. The amplification was
completed with a 10 min incubation step at 72°C, which ensured fully synthesized PCR
products.  Annealing temperatures (Tp) of primer oligonucleotides were calculated after
the empiric formula:
Tp = 22 + 1.46 x [2 x (G + C) + A + T]
Alternatively to this calculation the online software "oligonucleotide properties
calculator" was used [www.biotechlab.nwu.edu/Oligocalc.htm]. This software is based
on thermodynamic calculations by Breslauer et al., [Breslauer et al., 1986].
2.3.12. First strand cDNA synthesis
cDNA was synthesized according to the manufactures guidelines of the SuperScript III
RNase H- RT kit [Invitrogen, Carlsbad, CA].
2.4. Biochemical Methods
2.4.1. Protein concentration measurements after Warburg and Christian
This method by Warburg and Christian [Warburg and Christian, 1942/1942] is based on
extinction measurements of protein solutions in equilibrated quartz cuvettes at an UV
wavelength of 260 nm and 280 nm. The protein content of the solution is calculated
according to the following formula:
Cprotein (mg/ml) = E280 x 1.56 - E260 x 0.76
2.4.2. Protein measurements after Bradford
Protein concentrations were determined after the Bradford method [Sambrook et al.,
1989].
2.4.3. SDS polyacrylamide gelelectrophoresis after Laemmli
The electrophoretic separation of proteins according to their molecular weight was
performed in acrylamide gels as described by Laemmli [Laemmli, 1970]. Homogenous
10 cm wide and 8 cm high (small Biometra gel chamber [Biometra, Horsham, PA])
separating gels with acrylamide concentrations between 7,5% - 15% were used. All
stacking gels contained 5% acrylamide and were 30 mm long. Protein samples were
mixed 1:1 (v/v) ratio with 2x Laemmli buffer and denatured by boiling the sample for 5
min at 95°C. Electrophoresis was performed at a current of 10 - 20 mA at RT.
2.4.4. Silver staining of SDS polyacrylamide gels modified after Blum
In order to silver stain [Blum et al., 1988] a SDS-PAGE after electrophoresis, the gel was
fixed over night in solution 1. The next day, the gel was initially incubated for 40 min in
solution 2 (50% ethanol), and afterwards washed for 20 min in solution 3 (30% ethanol).
After an one minute incubation in solution 4 (thiosulfate) three washing steps (each 30
sec) in double distilled water (ddH2O) followed. After a 20 min incubation time in
solution 5 (silver/formaldehyde), two further washing steps (each 30 sec) in ddH2O
followed. The gel was developed in solution 6 (carbonate/formaldehyde/thiosulfate) until
the protein bands were clearly visible. The reaction was stopped by one quick wash step
in ddH2O, immediately followed by a 15 min incubation in solution 7 (methanol/acetic
acid). Before the gel was dried on a gel dryer, it was washed three times in water and
incubated for 30 min in 3% glycerol.
Solution 1: 50% methanol
       12% acetic acid
       0.5 ml/l formaldehyde (37%)
Solution 2: 50% ethanol
Solution 3: 30% ethanol
Solution 4: 0.2 g/l Na2S2O3 x 5 H2O
Solution 5: 2,0 g/l AgNO3
       0.75 ml/l formaldehyde (37%)
Solution 6: 60 g/l NaCO3
       0.5 ml/l formaldehyde (37%)
      4.0 mg/L Na2S2O3 x 5 H2O
Solution 7: 10% methanol
2.4.5. Coomassie staining of SDS polyacrylamide gels modified after Wilson
SDS polyacrylamide gels were incubated for at least 30 min at RT in Coomassie staining
solution [Wilson, 1983]. To reduce the background, gels were incubated in the de-
staining solution until clear proteins bands became visible.
Coomassie staining solution: De-staining solution:
Serva blue B: 1.75 g Methanol: 25%
Methanol: 454 ml Acetic acid: 10%
ddH2O: 454 ml
Acetic acid: 92 ml
2.4.6. Western blot modified after Towbin
Western blotting was used for specific identification of low concentrated proteins (in ng
range). After the denatured proteins were separated on a SDS-PAGE, the protein bands
were transferred on a Trans-Blot pure nitrocellulose membrane [BioRad, Hercules,
CA]. For this procedure, a Trans-Blot wet blotting cell [BioRad, Hercules, CA] was
used and blotting was performed for one hour at a current of 0.8 mA/cm2 membrane
[Towbin et al., 1979]. After blotting, free binding sites on the nitrocellulose membrane
were blocked in TBT buffer [Sambrook et al., 1989] supplemented with 5% (w/v) skim
milk powder over-night at 4°C.  Next day, the detection antibody (1st antibody) was
applied to the membrane in a 1:500 dilution (diluted in TBT buffer) and incubated for 3 -
16 h at 4°C. Afterwards, unbound antibody residues were removed by washing the
membrane twice for 30 min in TBT buffer at RT. To specifically detect the first antibody,
the membrane was incubated for one hour at 37°C with the corresponding HRP-labeled
secondary antibody (diluted 1:5000 in TBT buffer). Again, two washing steps for 30 min
at RT in TBT buffer removed excess antibody.
To detect the according protein band, the membrane was incubated with the colormetric
substrate of the ECL  Western blotting detection system [Amersham Bioscience,
Buckinham, UK] according to the maker. The band was made visible on a Kodak Biomax
MS film [Eastman Kodak company, Rochester, NY].
3. Results
3.1. Specific Aim 1: Develop a retroviral based point mutation indicator
system.
3.1.1. Expression of activation induced cytidine deaminase (AID) in 18-81 cells
Activation induced cytidine deaminase (AID) is the absolutely required trans-acting
factor to induce somatic hypermutation in activated B-cells. To verify that AID was
expressed in the continuously hypermutating 18-81 cell line, equal amounts of whole cell
lysate from three cell lines was separated on a 10% SDS-PAGE and AID expression was
detected by western blot. The NIH/3T3 fibroblast control did not show any AID
expression nor did the 70Z/3 hybridoma cell line (Fig. 4). Only the 18-81 cell line
expressed the 25 kDa protein. Smaller products were detected in some AID Western blots
(data not shown) those products were interpreted as splice variants rather than
degradation products. Later, this assumption was verified by McCarthy et al. [McCarthy
et al., 2003].
Figure 4. Western blot analysis of endogenous AID
expression in 18-81 cells, NIH/3T3 cells, and in 70Z/3
cells. 100 µg whole cell lysate (estimated by Bradford
method) of various cell lines was separated on a 10%
SDS-PAGE and AID was detected using a polyclonal
rabbit-anti-AID serum. Lane 1, 18-81 lysate; lane 2,
NIH/3T3 lysate, lane 3: 70Z/3 lysate. To the left of the
blot, molecular weight markers; to the right, position of
AID.
3.1.2. High virus titer production
Initially, the MoMuLV based retroviral vectors pLNCX2-eGFP and CRU5-IRES-eGFP
were tested for high virus titer production in the Phoenix E packaging cell line. The
CRU5-IRES-eGFP vector [J.B. Lorens, unpublished] is derived from the p96-dsG
plasmid [Lorens et al., 2000]. The CRU5 vector contains a composite CMV promoter
fused to the transcriptional start site of the MoMuLV R-U5 region (CRU5) located in the
5'LTR (Fig. 3). Whereas the CMV promoter allows high titer virus production during
transient transfection of Phoenix packaging cells, the provirus is expressed by the
retroviral MoMuLV LTR promoter after its integration into the host cell genome [Lorens
et al., 2000; Swift et al., 1999]. Further, the CRU5 vector contains a so-called extended ψ
packaging signal for improved encapsidation of retroviral mRNA (Fig. 3). The pLNCX2-
eGFP vector is based on the pLNCX2 vector [BD Biosciences Clontech, Palo Alto, CA]
and contains a regular MoMuLV 5' LTR promoter for virus production in the packaging
cell line and a regular MoMuLV packaging signal (Fig. 3). After integration of the
pLNCX2-eGFP provirus into the host cell genome, the CMV immediate early promoter
triggers GFP expression (Fig. 3 and Fig. 6).
Virus production rates of the two vector types were compared by transient transfection of
the Phoenix E packaging cell line. After three days of incubation, transiently transfected
Phoenix cells were analyzed for GFP expression by analytical flow cytometry. The
average transfection efficiency of the 102.IG construct was approximately three times
higher than for the pLNCX2-eGFP construct (Fig. 5A). Further, the pLNCX2-eGFP
construct showed an approximately three times lower relative GFP fluorescence intensity
(x-mean = 398) than the 102.IG construct (x-mean = 1124) (Fig. 5A). To investigate if
GFP expression correlates with virus production, the virus containing supernatant from
the transiently transfected Phoenix E cells was used to infect 18-81 cells. Seventy-two
hours after transduction, 18-81 cells were analyzed for GFP expression by analytical flow
cytometry. On average, 0.1% of the 18-81 cells were transduced with the pLNCX2-eGFP
construct and 10% of the 18-81 cells were transduced with the 102.IG construct (Fig.
5B). Low transfection and transduction rates of the pLNCX2-eGFP vector were
explained by promoter interference between the LTR and the CMV promoter, in that both
promoters might compete over shared transcription factors (compare discussion). Further
the extended packaging signal of the CRU5 vector may have contributed to improve
encapsidation of the retroviral mRNA.
Figure 5. Flow cytometry analysis of GFP expressing cells. Fluorescent positive cells were gated, and
transduction rates and relative x-means were determined. Transiently transfected Phoenix E cells (A) and
transduced 18-81 cells (B) expressing the retroviral CRU5-IRES-GFP (IG) or pLNCX2-eGFP vector,
respectively.
3.1.3. Retroviral backbone
Since the CRU5-IRES-eGFP vector produces two orders of magnitude more infectious
virus particles as compared to the pLNCX2-eGFP vector, all mutation indicator plasmids
described in this thesis and represented in Fig. 6 are based on the retroviral CBRU5-IRES
vector backbone. Because retroviral vectors integrate randomly into the host cell genome
via their LTR region [van der Putten et al., 1981], positional effects of integration play
less of a role. Furthermore, for infections I worked with a high cell to virus particle ratio,
so that only one retroviral copy, or less, was integrated per cell. And, by working in large
multi-clonal cultures, Luria-Delbrück fluctuation was avoided.
The basic mutation indicator system contained a fluorescence marker with a premature
TAG (amber) stop codon. The stop codon is embedded in the RGYW [R = purine, Y =
pyrimidine, W = adenine or thymidine] hot spot motif for hypermutation, in which
typically the guanine is mutated [Rogozin and Kolchanov, 1992, Bachl et al., 1997].
Upon reversion, a full-length fluorescent protein is expressed. Any single point mutation
at the amber stop codon activates the reporter—except the transition from G to A, which
only creates the ochre stop codon TAA. In the construct, the reporter gene is followed by
an internal ribosomal entry site; and a second marker that allows selection of stably
transduced cells. As reporter gene, the green and yellow fluorescence proteins (GFP and
YFP, respectively) as well as various proteins with red fluorescence (DsRed) were tested.
The second marker was either a drug resistance gene, or a second fluorescent protein. I
also introduced various cis-acting enhancer elements into the reporter construct, to study
the simultaneous activity of enhancers on transcription and hypermutation. Transduced
cells were either drug selected, or FACS sorted by fluorescent protein expression.
Figure 6. Schematic of CRU5-IRES based indicator vectors. IRES = internal ribosome entry site, DsRed537
= mutated DsRed2 red fluorescence protein, GFP = enhanced green fluorescence protein, YFP = enhanced
yellow fluorescence protein, Rm = DsRed537 red fluorescence protein, Eµ = 1 kb immunoglobulin heavy
chain intronic enhancer, κi = 721 bp kappa light chain intronic enhancer fragment, κ3' = kappa light chain 3'
enhancer, SV40 = SV40 enhancer, CMV IE = CMV immediate early promoter, stop, *, (X) = TAG amber stop
codon embedded in RGYW mutational hot spot motif.
In some experiments, pre-existing fluorescent revertants were purged from the culture by
sorting.
3.1.5. GFP family members
In the past, we and others have used the GFP gene to create a point mutation indicator
construct to study hypermutation [Bachl and Olsson, 1999; Wang et al., 2004]. Because
of the ease of use in flow cytometry and the familiarity with its characteristics, it seems
natural to turn to any of the other GFP family members—yellow fluorescence protein
(YFP), cyan fluorescent protein (CFP), and blue fluorescence protein (BFP)—for
alternative point mutation indicators (Fig. 6). Indeed, YFP and GFP can be easily
separated by flow cytometry, when the proteins are expressed in separate cells. Fig. 7,
first row, shows the flow cytometry profiles of NIH/3T3 cells transduced with a vector
containing YFP only (denoted Y); a vector containing an IRES followed by GFP (IG);
and of a mixture of such cells. Clearly, there is no interference in flow cytometry of cells
expressing either YFP or GFP. This also held true when NIH/3T3 cells were transduced
with the Y vector first, and then with the IG vector (Y/IG cells), or with the IG vector
first, and then with the Y vector. (Fig. 7, second row). The cells were not sorted before or
after the second infection. It is curious though, that in the second round of infection much
less cells were transduced. Because the virus did not produce envelope, superinfection
ought not be inhibited. At any rate, some cells apparently were transduced by both
constructs (third profile and fourth profile, upper right quadrant); some cells were not
transduced by the Y vector (first), but by the IG vector in the second infection (third
profile, lower right quadrant); or not transduced by the IG vector (first), but by the Y
vector (fourth profile, upper left quadrant). These results seem to enable the simultaneous
use of YFP and GFP mutation indicators in the same cell. But when it later comes to
sequencing of the mutation indicator, template switching during a PCR amplification and
cloning step may complicate the identification and characterization of mutants.
In addition to the pitfall mentioned above, the extensive similarity of their DNA
sequences precludes the combination of any GFP familiy genes (YFP, BFP, CFP, GFP)
within the same retroviral vector backbone. Even though, such constructs may be useful
to monitor transcription and mutability concomitantly. However, during reverse
transcription of the viral RNA into cDNA, this similarity causes the retroviral reverse
transcriptase to switch templates, resulting in recombinant molecules [Liu et al., 2002;
Svarovskaia et al., 2000]. I confirmed this well documented phenomenon by combining
the (enhanced) YFP gene with the GFP gene in the same vector. In the constructs, the
YFP gene, which either contained a premature termination codon (denoted Y(X)-IG), or
did not contain it (denoted Y-IG), was placed 5' to the internal ribosomal entry site
(IRES), followed by the (enhanced) GFP gene in the standard retroviral backbone vector
used throughout the work described here. These vectors were packaged into viral
particles and introduced to the hypermutating 18-81 cells by infection. Furthermore, to
exclude RAG-induced recombination and mutator induced reversion of the stop codon,
NIH/3T3 fibroblasts, which are both RAG and mutator negative, were also infected. In
flow cytometry, both transduced 18-81 cells (data not shown) and NIH/3T3 cells (Fig. 7,
third row) showed multiple cell populations, some of which co-expressed YFP and GFP,
while others expressed GFP or YFP only. In cells transduced with a Y-IG construct, two
major YFP and GFP double-producer populations were present, sandwiching two minor
double producer populations. Even in the Y(X)-IG construct, in which a premature stop
codon ought to prevent YFP from being translated, there are two major double producer
populations, along with one minor double producer population (at the diagonal), and
some YFP only cells. While I attribute the existence of the major double producers to
template switching in a way that the recombination occurred before the premature stop in
the YFP, I think that the minor populations represent stop codon revertants due to the
error prone retroviral reverse transcriptase.
Figure 7. Flow cytometry analysis of YFP and GFP expressing NIH/3T3 cells. Cells were transduced with
YFP (102.Y) or GFP (102.IG) containing vectors individually (first row), sequentially (second row, panel 3
and 4) or both fluorescence proteins were expressed by one plasmid (third row) (102.Y-IG). Y = eYFP, G =
eGFP, I = IRES, Y(X) = eYFP with amber stop codon.
3.1.6. A silent point mutation in DsRed resulting in enhanced relative fluorescence
intensity
To avoid the two—quite different from each other—template switch phenomena, I
looked at fluorescent proteins that are not derivatives of GFP. Furthermore, I wanted to
generate an indicator that can be assayed in the red channel in the flow cytometer. The
protein DsRed2 has only 23% DNA sequence similarity to GFP [Yarbrough et al., 2001]
and is a candidate for such an indicator. DsRed2 is an improved variant of DsRed, which
was originally cloned from a coral of the Discosoma genus [Matz et al., 1999]. DsRed2
was shown to be less toxic because of its increased solubility than the original DsRed and
the protein matured faster, which reduces the time from transfection to detection [BD
Biosciences Clontech, Palo Alto, CA]. Particularly, its emission maximum at 587 nm
makes it easy to separate from GFP with an emission maximum at 508 nm. For
expression in mammalian systems, the gene was codon optimized according to the human
codon usage table for highly expressed genes [Haas et al., 1996], to now have all serines
encoded by the predominant UCC codon. In human cells, UCC recruits an abundant
serine tRNA with a frequency of 17.8 times per 1000 codons [http://www.kazusa.or.jp/
codon/]. The UCA codon, which also incorporates serine, is less frequent (12.3 times per
1000 codons). Furthermore, between human and mouse, the UCC to UCA tRNA ratios
differ only slightly with 1.46:1 and 1.57:1, respectively.
In my cloning strategy I needed to destroy the BstXI restriction site at nucleotide position
537 in the DsRed2 gene in order to integrated it into the BstXI site of the 102.IG vector.
To obtain this mutant, the pDsRed2-1 served as PCR template for site directed PCR
mutagenesis in which I mutated the serine codon UCC at aa position 179 to a UCA codon
in the DsRed2 gene. Because the procedure replaced the cytidine by an adenosine at
nucleotide position 537, the mutated gene was designated DsRed537. To compare
mutated and original DsRed, both genes were cloned into the XhoI and NotI restriction
sites of the 102.IG vector replacing the IRES-GFP fragment (Fig. 5). The CRU5 vector
allows to either transiently express DsRed directly from the plasmid, driven by the CMV
promoter, or by the retroviral MMLV promoter after stable integration of the provirus
into the host cell genome. To produce retroviral particles, Phoenix E packaging cells
were transiently transfected. For transduction, NIH/3T3 cells and the murine 18-81
lymphocyte line were spin-infected with the virus containing supernatant from
transfected Phoenix E cells. The transduced cells were analyzed after 3 and 5 days by
flow cytometry on a FACS Calibur . Because the construct copy number per cell
influences relative fluorescence intensity, samples with identical transduction rates were
compared.
A direct correlation between expression rate and representation of rare versus common
tRNAs has been extensively documented [Grosjean and Fiers, 1982; Holm, 1986].
According to these reports, if the switch of the UCC codon to the slightly less favorable
UCA codon would directly translate into gene expression levels, one would predict a
slight reduction of relative fluorescence intensity for the mutated DsRed protein. But
surprisingly, the single base pair substitution resulted in an increase, rather than in a
decrease, in relative fluorescence intensity (Fig. 8). The relative fluorescence intensity of
DsRed537 was increased 3.6 fold in the NIH/3T3 line (Fig. 8A) and 4.1 fold in the 18-81
line (Fig. 8B). Even in DsRed-Express1, which is an improved variant of DsRed2 in that
it shows a much higher fluorescence intensity from the beginning [Bevis and Glick,
2002], the same single base pair substitution resulted in a 1.5 fold increase in NIH/3T3
cells (Fig 8A, second row). Because the single base pair substitution presumably has no
effect on the transcription of the gene, and the amino acid sequence has not changed, the
effect ought to be at the mRNA or translational level (compare discussion). Besides
several other explanations, it is possible that tRNA depletion occurs during translation of
over-expressed genes (compare discussion).
Figure 8. Flow cytometry analysis of DsRed expressing cells. Fluorescent positive cells were gated, and
transduction rates and relative y-means were determined. NIH/3T3 cells (A) and 18-81 cells (B) transduced
with the retroviral CRU5-DsRed2, CRU5-DsRed537, CRU5-DsRed-Express1 and CRU5-DsRed-
Express537, respectively.
3.1.7. Alternative red fluorescence proteins
In Fig. 10, I tested three different versions of DsRed—DsRed537, HcRed and DsRed-
Express1 [CLONTECHniques, 2001]. The DsRed537 red fluorescent protein is a variant
I derived from the DsRed2 protein; it has an increased relative fluorescent intensity
[Klasen and Wabl, 2004]. HcRed had the advantage over the tetrameric DsRed537 of
being a dimeric protein, which is likely to be more soluble and thus less toxic to the cell
[Gurskaya et al., 2001], but it has the disadvantage that its excitation maximum is at a
wavelength of 588 nm. This requires a flow cytometer with a separate 568 nm laser line
at 200 mW in combination with a 640 nm long pass filter in the FL2 channel. Even under
these conditions, the relative fluorescent intensity of a 102.HcRed construct proved to be
lower than the one of DsRed537 (Fig. 10). Finally, DsRed-Express1 is an improved
variant of DsRed2 reported to be less toxic for the cell, better soluble, having a faster
maturation rate, and an improved fluorescent intensity [Bevis and Glick, 2002].
Theoretically, a clear separation from the GFP signal was possible, and when the same
flow cytometry conditions as those used for HcRed were applied, the results for DsRed-
Express1 looked promising (Fig. 10). I have not yet tested DsRed-Express1 for possible
toxicity, though. And quite recently, other fluorescent markers, such as the AsRed and
the AmCyan protein (Clontech, San Jose, CA) have become available and might offer
better solutions to the separation and toxicity issues.
Figure 10. Flow cytometry profiles of 18-81 cells transduced with the retroviral CRU5-HcRed, CRU5-
DsRed2, CRU5-DsRed537 and CRU5-DsRed-Express1 vector (Fig. 6), respectively. Cells were analyzed on
a MoFlow using a separate 568 nm laser line at 200 mW in combination with a 640 nm long pass filter in the
FL2 channel (first row) and on a FACS Calibur using standard settings (second row).
3.2 Specific aim 2: Characterize the IgH major intronic enhancer
and other enhancer elements, as cis-elements in hypermutation.
3.2.1. CRU5-Red537-IRES-GFP(X) constructs
In a first set of CRU5 constructs I introduced the amber stop codon into the GFP gene of
the IG vector, creating IG(X). The DsRed537 (Rm) gene was placed 5' to the IRES
segment, as a selection marker for stably transduced cells (Rm-IG(X)) (Fig. 6). To test
the activity of the Eµ intronic enhancer in this construct, it was placed 5' to the MoMuLV
3'LTR region. Even though the Eµ enhancer was reported to be the only cis-acting
element needed to target the mutator, placing it next to the 3'LTR enhancer could
extinguish its function by enhancer interference [Bachl et al., 1998]. Yet another
construct contained the Rm gene 5' to the IRES-GFP (Rm-IG) to express both DsRed and
GFP (two color control) simultaneously (Fig. 6).
The constructs were used to transduce 5 x 105 18-81 cells, which are active in
hypermutation [Wabl et al., 1985]. Measured by flow cytometry 3 days after
transduction, on average, 20% of all transduced cells expressed DsRed. To measure
mutation rates, 5 x 105 GFP expressing cells were sorted by FACS, and pre-existing
Rm(X) revertants were purged from the culture. All samples were set up in duplicates
and sorted cells were seeded into 50 ml medium. Cultures were slowly expanded to a
final volume of 400 ml over 14 days. Samples were analyzed every other day by flow
cytometry.
A clear identification of GFP(X) revertants by flow cytometry was not possible in this
approach (Fig. 11), because the DsRed protein emits light in the green fluorescence
spectrum during protein maturation (Fig. 11, second panel, population in the lower right
quadrant) [Baird et al., 2000]. This feature made it impossible to distinguish between
maturing DsRed expressing cells and real GFP revertants. Further, the signal of auto-
fluorescent dead cells interfered (Fig. 11, first panel). To investigate if real revertants
were covered by interfering cells, (maturing DsRed cells or dead cells) a gate was set for
potential DsRed537/GFP double positive cells in a Rm-IG(X) sample and single cells
were sorted into 94 well plates by FACS (Fig. 11, second row, second panel). Only 17
clones out of 94 seeded single cells grew. A result, which I interpreted as circumstantial
evidence, that dead cells have been sorted. The 17 subclones were expanded and genomic
DNA was extracted from those cells. Subsequently, the GFP gene was PCR amplified
and sequenced. Two of the 17 sequences did not show any homology to the GFP
sequence, which was probably due to unspecific PCR amplification. Six out of fifteen
clones showed a clear reversion of the amber stop-codon to the anticipated TAC codon
(G→C substitution)[Bachl and Wabl, 1996; Bachl et al., 1997; Bachl and Olson, 1999].
The remaining seven sequences showed a double peak at the stop codon. Six sequences
of those seven sequences showed a TAG peak under the TAC peak or vice versa (figure
12). If one excludes the possibility of a plasmid contamination during PCR or DNA
sequencing and cell contamination during FACS, the double peaks can be interpreted as
two integrated vectors per cell and only one integration site was mutated at the time of
the DNA sequencing analysis. Certainly, this finding would have to be proven by i.e.
Southern blotting. However, one of the seven clones showed also a double peak, but a
TAT codon was detected under a TAC codon. This mutation was particularly interesting
since the anticipated G→C substitution was detected for one integration site, only. At the
other integration site, the mutator system generated a C→T transition (Fig. 12). Further,
in one of the two sequences the TAT or TAC neighboring base pair was mutated. This
was the only GFP sequence, which showed additional mutations than the reversion of the
stop-codon.
However, since dead cells and DsRed maturing cells interfered with the GFP signal,
mutation rate measurements based on a reliable read out by flow cytometry were
impossible.
Figure 11. Flow cytometry analysis of 18-81 cells transduced with CRU5 indicator vectors. Live cells were
gated based on their appearance in the forward / sideward scatter. R = DsRed2, Rm = DsRed537, IG =
IRES-GFP, Eµ = 1 kb heavy chain large intronic enhancer, (X) = TAG stop codon. The gate in sample Rm-
IG(X) was set for single cell sorting into 94 well plates.
Figure 12. Chromatograms of selected DNA sequences from three individual single cell subclones after
FACS sorting for GFP(X) revertants. First panel: anticipated stop codon reversion from TAG to TAC (single
proviral copy). Second panel: presumably two proviral copies, one TAG to TAC reversion, one TAG
unreverted. Third panel: presumably two proviral copies, one reversion from TAG to TAC and one reversion
from TAG to TAT. Additional mutation next to the stop codon for one integration site (C→A substitution).
3.2.2. CRU5-DsRed537(X)-IRES-GFP vectors
In the following experiments the DsRed537 gene contained the amber stop codon, which
is embedded in the RGYW hot spot motif for somatic hypermutation, and the GFP gene
was used as selection marker for transduced cells. Initially I tested the activity of the
immunoglobulin Eµ intronic enhancer at two different positions in these reporter
constructs. The Eµ enhancer was placed 3' to the Rm(X) gene to target the mutator
complex to the red fluorescent reporter sequence (Fig. 6). In an additional construct, I
placed the Eµ intronic enhancer 5' to the 3'LTR region, where the MoMuLV enhancer is
located (Fig. 6). It was anticipated that the function of the Eµ would be extinguished by
interference from the LTR enhancer [Bachl et al., 1998]. Yet another construct, the
Rm(X)-IG vector did not contain any immunoglobulin specific DNA elements (Fig. 6).
Finally, because it did not contain any dsRed gene, the IG vector served as negative
control (Fig. 6).
The constructs were used to transduce 1 x 106 18-81 cells. Measured by flow cytometry 3
days after transduction, on average, 10% of all transduced cells expressed GFP. To
measure mutation rates, 1 x 106 GFP expressing cells were sorted by FACS, and pre-
existing Rm(X) revertants were purged from the culture (Fig. 13B, day 0). All samples
were set up in duplicates and sorted cells were seeded into 50 ml medium. Cultures were
slowly expanded to a final volume of 400 ml over 7 days. A sample was removed every
24 hours and the number of DsRed and GFP double positive cells among 1 million GFP
expressing cells was determined by flow cytometry (Fig. 13A). The first sample was
analyzed on day 2 after the sort and showed an average of 110 revertants for the Rm(X)-
Eµ-IG construct. The number of revertants per million cells increased linearly over the
next 5 days, and a mutation rate of 5 x 10-5 mutation/bp/cell generation was calculated. In
these experiments, the number of mutants for the Rm(X)-IG and the Rm(X)-IG-Eµ
vectors was under the detection limit. But I need to emphasize that due to the cut off line
that was set to separate the red cells from green cells bleeding into the red gate (Fig 14, y-
axis), approximately 2/3 of all mutants were not recorded (Fig. 13A, panel 4).
To verify that the revertants detected in the Rm(X)-Eµ-IG samples were due to true
reversion of the amber stop codon, GFP/DsRed double positive cells were sorted by
FACS, and the chromosomal DNA from these cells was extracted to be used as a PCR
template, subcloned into bacterial vectors and sequenced. Of 23 sequences, 22 had the
TAG stop codon mutated to TAC, and one to TAT. Additional mutations were found in 4
of the 23 sequences (Fig 14). This pattern has been observed repeatedly in the 18-81 cell
line, both at the endogenous IgH locus and at ectopic genes [Bachl et al., 1997; Bachl and
Wabl, 1996]. All of the additional mutations were C→T transitions, three of them on the
non-template strand and one on the template strand. Interestingly, only 2 out of the 4
additional mutations occurred within the RGYW hot spot motif.
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Figure 13. (A) Flow cytometry analysis of Rm(X) revertants in the hypermutating 18-81 line. IG = IRES-
GFP, Rm = DsRed537, (X) = amber stop codon, Eµ = 1 kb heavy chain intronic enhancer. (B) Somatic
hypermutation of the Rm(X) indicator in the presence and absence of the Eµ enhancer in the 18-81 line. x-
axis = time in days, y-axis = number of Rm(X) revertants per 1 x 106 GFP expressing cells.
Figure 14. Selected sequences from Rm(X) revertants, which show additional mutations. Mutations are
boxed. Position of mutations are indicated by the bp residue. DsRed (X) = DsRed537 gene with integrated
stop codon at bp 517. Clone # = E.coli plasmid number.
3.2.3. Cis-acting elements
In the next set of experiments I included various other enhancers into the reporter
constructs. The Eµ enhancer of the Rm(X)-Eµ-IG construct was replaced by the SV40
enhancer (to generate the Rm(X)-SV40-IG contruct); by the 803 bp kappa 3' enhancer
(Rm(X)-Κ3'-IG); and a 720 bp fragment of the kappa intronic enhancer, which lacked the
3' matrix attachment region (MAR) to target somatic hypermutation [Klix et al., 1998]
(construct Rm(X)-Κi-IG). GFP expressing cells, transduced with one of these constructs
each, were sorted and seeded in 100 ml medium, and the culture was expanded for 1 day
to a final volume of 200 ml. From then on the cultures were split in a 1:3 ratio every 24
hours. Samples were removed and analyzed by flow cytometry (Fig. 15). As expected,
the Rm(X)-Eµ-IG samples revealed the highest number of revertants (Fig. 15A). The
construct did also show a high transcription rate estimated by the relative x-mean (Fig.
15B, x-mean = 102). But the Rm(X)-SV40-IG samples showed almost as high numbers
of revertants as well, despite a lower x-mean (Fig. 15B, x-mean = 59). Inclusion of the
SV40 enhancer also gave the construct a higher mutability than the 3’ κ enhancer. And
the κ intronic enhancer had the smallest effect, but the construct was expressed best (x-
mean = 107). But even with no enhancer in close proximity to the Rm(X) gene revertants
were recorded (Fig 15A, sample Rm(X)-IG).
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Figure 15. (A) Time course of Rm(X) revertants under influence of various cis-acting enhancer elements. Y-
axis = number of Rm(X) revertants per 1 x 106 GFP expressing cells. X-axis = time in days, IG = IRES-GFP,
Rm = DsRed537, Eµ = 1 kb heavy chain intronic enhancer, SV40 = SV40 enhancer, κi = 721 bp fragment of
kappa light chain intronic enhancer, κ3' = kappa light chain large 3' enhancer, (X) = amber stop codon (B)
Relative GFP expression rates of reporter constructs containing various enhancers. Y-axis = relative GFP
fluorescence intensity. X-axis = construct, Eµ  = Rm(X)-Eµ-IG, SV = Rm(X)-SV40-IG, Ki = Rm(X)-Ki-IG, K3'
= Rm(X)-K3'-IG constructs
These experiments show that using the retroviral CRU5 reporter constructs to measure
mutation rates is reasonably fast and reliable. Yet, the engineered vectors leave some
room for potential improvement (compare discussion). Even though the increased relative
fluorescent intensity of the DsRed537 variant made a separation from the GFP signal in a
standard flow cytometry setting possible, 2/3 of the revertants were still covered by a
“hump” of the GFP signal alone. Sequencing the GFP gene from cells in the hump did
not show any mutations (data not shown). Further, the number of cells, which do not
express the indicator vector (i.e. get silenced) increased over the curse of the experiment
(Fig. 16). These observations led to switch to indicator vectors which contain the GFP(X)
gene together with an antibiotic resistance marker for selection of transduced cell on a
bicistronic message.
Figure 16. Silencing of retroviral reporter constructs over time based on Fig 13. Cell numbers were
estimated by setting a gate for non-expressing cells in the flow cytometry analysis. Rm(X) = DsRed537
containing the integrated amber stop codon, Eµ = 1 kb heavy chain intronic enhancer, IG = IRES-GFP, x-
axis: time in days, y-axis: number of silenced cells in percentage
3.3. Specific Aim 3: Somatic hypermutation and mismatch repair in non-B cells
With the following experiments, I wanted to answer the question whether mismatch
repair plays a role in hypermutation in cells other than B lymphocytes. In one sense, this
question is tautological; clearly, if all introduced mutations were repaired, no mutations
would be seen. But, somewhat counter-intuitively at first, we and others found that in B
lymphocytes the mismatch repair system may be modified in such a way that it actually
introduces mutations rather than corrects them. Previously, subclones of the human 293T
kidney cell line had been constructed in such a way that the expression of MLH1 can be
controlled by tetracycline [Trojan et al., 2002]. This gave as an opportunity to study the
influence of MMR in AID mediated hypermutation.
3.3.1. AID expression in NIH/3T3 cells
I first wanted to make sure that the AID I cloned from the 18-81 cell line mediates
hypermutation, when transduced into non-AID expressing cell lines. I used the pLNCX2-
mAID vector for ectopic AID expression in NIH/3T3 cells. AID expression was tested by
Western blot (Fig. 17). While the non-transduced NIH/3T3 cells contain no band
representing AID (Fig. 17, lane 2), the transduced cells show a strong band at just below
25 kDa representing AID. However, compared to the endogenous AID expression of 18-
81 cells (Fig. 17, lane 1), there was less AID protein expressed in the transduced
NIH/3T3 cells.
To investigate whether the cloned AID would induce somatic hypermutation in non-AID
expressing cell lines, I used the reporter constructs pGFP*-Ipuro (GFP*) and pGFP*-
Emu-Ipuro (GFP*E) [Wang et al., 2004] (Fig. 5). These reporters contain an enhanced
green fluorescent protein gene (GFP) with a premature termination codon (*), embedded
in a RGYW hot spot motif for somatic hypermutation [Rogozin and Kolchanov, 1992;
Betz et al., 1993; Bachl et al., 1997; Bachl and Olson, 1999]. Upon reversion of the stop
codon, full-length GFP protein is expressed and the cell fluoresces, which is detected by
flow cytometry. The reporter constructs encode the puromycin resistance gene on one
bicistronic message together with the GFP gene (Fig. 5). Transduced cells were selected
with 2.5 µg/ml puromycin. I introduced this reporter into duplicate NIH/3T3 cell cultures,
and subsequently, the cells were transduced with the pLNCX2-mAID retrovirus. The
empty pLNCX2 vector served as mock control. Stably transduced cells were selected
with 100 ng/ml neomycin and selection pressure on both the AID expression vector and
the reporter was maintained during the entire experiment. Samples were taken and GFP*
reversion was analyzed by flow cytometry at multiple time points (Fig. 18). In these
experiments, I actually used two kind of reporters—one contained the GFP* as the
Figure 17. Western blot analysis of AID expression in 18-
81 cells, and in NIH/3T3 cells transduced with the pLNCX2-
mAID retroviral expression vector. Upper portion of the blot,
developed with antibody to AID; lower portion, developed
with antibody to actin. Lane 1, 18-81 line; lane 2, NIH/3T3
line; lane 3, NIH/3T3 line transduced with AID. To the left of
the blot, molecular weight markers; to the right, position of
AID and actin, respectively.
essential gene, and another had in addition the large IgH intronic enhancer (Eµ). This Ig
locus element was described to increase mutation rates for ectopic Ig genes [Bachl et al.,
1998], but not the ectopic GFP reporters used here [Wang et al., 2004; Spillmann and
Wabl, 2004; Klasen et al., 2004]. In the experiments described here, it did not make
much difference whether or not the reporter contained Eµ. In fact, at 2 x 10-5 per day, the
reporter without Eµ (Fig. 18, open circles) even mutated with a somewhat higher rate
than the one with Eµ, at 1.2 x 10-5 per day (Fig. 18, filled circles).
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Figure 18. AID mediated somatic hypermutation in NIH/3T3 fibroblasts. Y-axis: number of GFP* revertants
per 1 x 106 live cells. X-axis: time in days. Open circles, AID-transduced cells containing GFP* reporter
without Eµ enhancer (Emu-); filled circles, AID-transduced cells containing GFP* reporter with Eµ enhancer
(Emu+). Open squares, mock (with pLNCX2) transduced cells containing GFP* reporter without Eµ
enhancer (Emu-); filled circles, mock transduced cells containing GFP* reporter with Eµ enhancer (Emu+).
Open and filled triangles, cells containing GFP* reporter only, without (Emu-), or with Eµ enhancer (Emu+),
respectively.
Importantly, the mutation frequencies increase for both constructs with time, while there
is no such increase for cells without AID (Fig. 18, empty and filled squares represent
mock-transfected cells; and empty and filled triangles represent cells with reporter only).
Taking into account that the fibroblasts divide once in 24 hr, a mutation rate of 1.2 x 10-5
and 2 x 10-5 mutations/bp/ cell generation was calculated. This rate is comparable to the
rate of GFP* in the 18-81 cell line (1.0 x 10-5) [Bachl and Wabl, 1996; Green et al.,
1995], which expresses AID endogenously, but ten times lower than the one at the
endogenous VH, with 0.3 - 1 x 10-4 mutations/bp/cell generation, in the 18-81 cell line
[Wabl et al., 1985].
3.3.3. Hypermutation in the presence and absence of mismatch repair
Having successfully tested the activity of our ectopic AID construct in NIH/3T3 cells, I
turned to study the influence of the mismatch repair system on somatic hypermutation in
cells other than activated B cells. I took advantage of the 293T-Tet-Off-hMLH1 cell
line—a kidney cell line, in which the expression of MLH1 can be controlled by
tetracycline or its analogs; in this cell line, a transgenic MLH1 gene under the control of
the Tet-off inducible system has replaced endogenous MLH1 gene expression [Trojan et
al., 2002]. MLH1 repression was tested by Western blot by adding 50 µg/ml doxycyclin
to the culture medium for 7 days (Fig. 19A, left lane). To detect small amounts of MLH1,
the SDS-gel was overloaded with 400 µg whole cell lysate. Under these conditions, no
MLH1 protein could be detected, although in the absence of doxycyclin MLH1 was well
expressed (Fig. 19A, right lane).
Next the modified 293T cell line was transduced with mutation reporter constructs and
selected for stable integration. Then the culture was split into two parts, and for five days,
the one aliquot was grown in medium containing doxycycline to repress MLH1
expression, whereas the medium of the other aliquot contained no doxycycline. Both of
these cell cultures—one expressing MLH1 and the other not—were transduced with the
retroviral construct that contains AID (pLNCX2-mAID). All transduced cells were kept
under selection with 0.5 µg/ml puromycin, for the indicator plasmid, and with 500 ng/ml
neomycin, for the AID expression vector, during the entire experiment. All cultures were
also set up in duplicates, and samples were taken for the determination of mutation
frequencies by flow cytometry over a period of 28 days. On day 30 of the experiment, the
performance of the Tet-off system was tested by Western blot analysis again; i.e., was the
MLH1 expressed in the appropriate cell lines? Fig. 19B shows that this indeed was the
case. No MLH1 protein was detectable in doxycyclin treated cultures (Fig. 19B, lanes 2
and 3), but MLH1 was well expressed in cultures without doxycyclin (Fig. 19B, lanes 1
and 4).
In these experiments, parallel culture sets were tested with reporter constructs with
(GFP*E) and without (GFP*) the large intronic enhancer Eµ. I took flow cytometry
measurements of GFP revertant frequencies in the various cultures over a period of 28
days. Unlike in the experiments with the NIH/3T3 line, where addition of the Eµ had a
slight negative effect on the mutability of the reporter gene, in the 293T line, the Eµ
increased the mutation frequency (Fig. 20, filled and empty diamonds; 4 x 10-6/day)
approximately two-fold over the one in the construct without Eµ (rectangles; 2.1 x 10-
6/day). However, MLH1 expression did not have any influence on the mutation rate in
this system. Thus, whether (Fig. 20, filled diamonds and rectangles) or not (Fig. 20, open
diamonds and rectangles) the cells expressed MLH1, there was no difference in mutation
frequencies.
A B
Figure 19. Western blot analysis of MLH 1 expression in human 293T-Tet-Off-hMLH1 cells, developed with
antibody to MLH1. (A), before the experiment 18-81 cells; and (B), at day 30 of the experiment. To the left of
the blots, molecular weight markers; to the right of blot (B), position of MLH1. Same protein amounts were
applied in all lanes. Above the individual lanes: “off”, 50 µg/ml doxycyclin; “on”, no doxycyclin. GFP*, GFP
reporter without Eµ enhancer; and GFP*E, reporter with Eµ enhancer.
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Figure 20. AID mediated somatic hypermutation in the presence and absence of MLH1. Y-axis: number of
GFP* revertants per 1 x 106 live cells. X-axis: time in days. Diamonds, cells containing GFP* reporter with
Eµ enhancer (Emu+); AID-transduced (AID+); and MLH expressing (MLH+; filled diamonds), or MLH-non-
expressing (MLH-; open diamonds). Squares, cells containing GFP* reporter without Eµ enhancer (Emu-);
AID-transduced (AID+); and MLH expressing (MLH+; filled squares), or MLH-non-expressing (MLH-; open
squares). Open and filled triangles, cells containing GFP* reporter only, without (Emu-), or with Eµ enhancer
(Emu+), respectively.
4. Discussion and conclusions
4.1. Specific Aim 1: Develop a retroviral based point mutation indicator system.
4.1.1. High virus titer production
The results of the comparison between the pLNCX2 vectors and the CRU5 vectors were
not surprising since the CRU5 vector was optimized to gain high virus titers in the
Phoenix cell line [Lorens et al., 2000; Swift et al., 1999; Pear et al., 1993; Danos and
Mulligan, 1988]. On the other hand it was not anticipated that the pLNCX2-eGFP
plasmid would produce that little amounts of virus particles. It can be assumed that
promoter/promoter and promoter/enhancer interference contributed to the poor pLNCX2-
eGFP virus titers, in that, the MMLV and the CMV promoter would compete over
common transcription factors [Lorens et al., 2000]. This would explain the comparable
low relative fluorescence GFP intensity of the pLNCX2-eGFP construct in the Phoenix
cell line and the low infection rate of 18-81 cells with the pLNCX2-eGFP virus. Because
less retroviral transcripts were made in the first place, which ultimately results in low
virus titers. Additionally, transcription initiation at the CMV promoter could interfere
with the elongation of the full size retroviral transcript initiated by the MMLV promoter
of the pLNCX2-eGFP construct during virus production in the Phoenix line. Another
source for interference could be the short GFP mRNA product generated under the CMV
promoter, which could hybridize with the template DNA strand. In this respect a
bicistronic strategy as developed for the CRU5 vector, in which only one transcript is
made, has major advantages during virus particle production in the Phoenix cell line.
Certainly, the extended ψ packaging signal of the CRU5 vector does improve the
encapsidation of the viral mRNA in the Phoenix packaging cell line further, which also
contributes to high virus titers [Lorens et al., 2000]. These results clearly favor the CRU5
bicistronic retroviral vector over the pLNCX2 vector.
4.1.2. CRU5 based retroviral reporter constructs
Using the retroviral CRU5 reporter constructs we could show that measuring mutation
rates is reasonably fast and reliable. The large number of integration sites mitigates a
position effect that invariably comes into play in cultures of cells with a single integration
site, as is the case with stable transfectants. Transducing large numbers of cells
circumvents time consuming subcloning and compartmentalization tests, which are
necessary when low numbers cause fluctuation. However, there certainly is room for
potential improvement on this type of vectors. For example, silencing of the provirus by
methylation of the LTR promoter/enhancer region is an extensively reported host defense
mechanism against retroviruses [Svoboda et al., 2000; Robbins et al., 1998]. This has no
influence on constructs that can be kept under drug selection pressure, but it has been an
issue for the construct without such selection.
An improvement might be achieved with so-called "sin-vectors", in which the LTR
promoter/enhancer is deleted in the provirus. In these vectors, silencing via methylation is
thought to be reduced, and, in some cases, not even detectable [Lorens et al., 2000;
Pfeifer et al., 2002]. Expression of the mutation indicator cassette would then be
triggered by a promoter located immediately 5' of it [Lorens et al., 2000]. This approach
would have two other advantages. First, it would be possible to reduce the distance
between promoter and indicator sequence. In vivo, the mutation rate at the V(D)J and VJ
region is highest in close proximity to the promoter (with an approx. 200 bp spacer
between promoter and target sequence) and decreases with increasing distance from the
promoter [Lebecque and Gearhart, 1990; Rada et al., 1997]. In our CRU5 constructs, the
MoMuLV promoter is separated from the indicator gene by the 1283 base pair ψ
packaging signal, which may explain the lower mutation rates measured with this
indicator plasmids, as compared to other measurements in the 18-81 cell line [Bachl and
Wabl, 1996; Bachl et al., 1999; Bachl and Olsson, 1999; Bachl et al., 2001]. Second, an
enhancer-less promoter, such as the thymidine kinase promoter, would allow a better
controlled study of putative mutation enhancers.
On the other hand, sin-vectors would encode two promoters in the plasmid stage (the
3'LTR promoter and the internal promoter) when expressed in the Phoenix packaging
line. This can results in low virus titers due to promotor/promoter interference,
transcription elongation, and short mRNA interference as discussed for the pLNCX2
vector. In this respect a bicistronic strategy as developed for the CRU5 vector, in which
only one transcript is made, has major advantages during virus particle production in the
Phoenix cell line.
Alternatively, lentiviruses may be beneficial since they yield higher transduction rates,
and they can infect non-dividing cells, which may help in studies on the influence of cell
division on hypermutation [Logan et al., 2002]. To completely exclude positional effects,
episomal adenoviral vectors might be applicable, because they do not integrate into the
host genome [Ehrhardt et al., 2003]. Today these vectors still do have the disadvantage of
introducing high plasmid copy numbers per transfected cell (1 - 100 copies) and low
transfection rates [Colosimo et al., 2000].
4.1.3. Fluorescence marker genes versus antibiotic selection markers
These and other studies showed that drug selection seems to be the most straightforward
way to measure relative mutation rates on stably expressed indicator genes [Wang et al.,
2004; Spillmann and Wabl, 2004; Klasen et al., 2004]. However, because transcription
rates correlate directly with hypermutation rates, for a limited antibiotic dosage range
high mutation rates would change with the degree of antibiotic selection pressure.
Furthermore, increased antibiotic selection pressure may increase the cytotoxicity of the
reporter gene, as is the case for the DsRed tetramer.
Further, certain proviral integration sites in the host genome could support expression of
the selection cassette, which would ultimately lead into a growth advantage of those cells.
After a few cell generations one would measure mutation rates of some predominant
clones, which support proviral expression. By using fluorescence marker genes this
selection criteria were circumvented. Unless, expression of a fluorescence marker would
increase cell proliferation, but this is a purely theoretical scenario which has not been
reported so far.
4.1.4. DsRed
Used alone, DsRed is a viable alternative to the GFP. However, in combination with (all
cells also expressing), the GFP signal bleeding into the DsRed channel during flow
analysis can pose a problem. Even though the increased relative fluorescent intensity of
the DsRed537 variant made a separation from the GFP signal in a standard flow
cytometry setting possible, 2/3 of the revertants were still covered by a “hump” of the
GFP signal alone. Sequencing the GFP gene from cells in the hump did not show any
mutations (data not shown). I hypothesize that the hump might be due to dying cells,
even though the cells would still be recorded as live cells in the forward/sideward scatter
of the flow cytometer. Thus, the increased relative fluorescent intensity of the improved
DsRed537 was still not optimal. As potential alternatives, HcRed and DsRed-Express1
have become commercially available [CLONTECHniques, 2001]. The results for DsRed-
Express1 looked promising since a clear separation from the GFP signal was theoretically
possible. However, DsRed toxicity combined with silencing of the retroviral reporter may
be problematic in long-term experiments.
4.1.5. A silent point mutation in DsRed resulting in enhanced relative fluorescence
intensity
Since the single base pair substitution in DsRed537 has not changed the amino acid
sequence and presumably has no effect on the transcription of the gene, the effect ought
to be at the mRNA or translational level.
Initiation of mRNA translation is the same for both transcripts, but the elongation at the
mutated site might be affected. The point mutation could have altered tertiary mRNA
structure and, therefore, have improved processivity of the ribosomes. However, the
mRNA prediction software mfold [http://www.bioinfo.rpi.edu/applications/mfold/old/
rna/] did not show any changes of mRNA structure. Another possibility could be an
increase in mRNA stability; but theoretically, the less frequently used codons decrease it
[Kennell, 1986]. Other explanations include the influence of flanking codons on codon
usage at particular sites. The so-called "codon-context effect” has been found in various
species; it describes the finding that some major codons are not used preferentially at all
sites [Morton and So, 2000]. The effect is presumably due to codon-codon interaction
during translation [Shpaer, 1986]. A more complex explanation for our findings would be
decreased differences in the energy of codon-anticodon pairing during the elongation
phase [Thomas et al., 1988].
Besides these explanations, it is possible that tRNA depletion occurs during translation of
over-expressed genes. I here suggest that in highly expressed genes, the tRNA with the
anticodon corresponding to a commonly used codon might become depleted. As a
consequence, overall less protein is synthesized, but mRNAs using less frequent codons
at some positions may be translated more efficiently. So far, the tRNA drop-off
phenomenon has been shown only under starvation conditions for aminoacylatable tRNA
in E. coli and in vitro [Menninger, 1978], but it seems to be an attractive explanation for
this study. Because all serines in the DsRed gene are encoded by the UCC codon,
substituting one UCC by an UCA codon makes available an entirely unused tRNA pool.
At any rate, besides the general codon optimization rules, my data suggest a more
detailed consideration of tRNA kinetics, especially, when tRNA pools are represented at
equal levels.
4.2. Specific Aim 2: Characterize the IgH major intronic enhancer and other
4.2.1. Cis-acting elements in somatic hypermutation
Because none of our constructs needed to contain an Ig sequence, we confirmed our
previous findings that no Ig specific sequence is needed to target the mutator [Wang et
al., 2004], at least on exogenous substrates. The question whether (Ig and non-Ig)
enhancers have a direct effect on hypermutation, or only via their effect on transcription,
was not answered in a simple way. Because all our reporter constructs contain the
MoMuLV enhancer in the LTR regions, we could not rule out that enhancer elements are
needed for hypermutation in a direct way. As described above, working with sin-vectors
would resolve this issue. But are enhancer elements needed that are Ig-locus specific? It
was suggested by Michael et al. that E-box motifs have an influence on mutation rates
[Michael et al., 2003]. E-box motifs are distributed in the IRES and LTR enhancer
sequences in the reporter constructs, and thus one cannot rule out that they are directly
responsible for a high mutation rate. But certainly, these motifs are not unique to the Ig
enhancers. Besides their presence in the IRES and LTR enhancer, additional E-box
motifs were also introduced with the Eµ, κ intronic and κ 3' enhancer elements, but not
with the SV40 enhancer. Still, the SV40 enhancer, with a lower expression rate than the κ
intronic enhancer, gave a higher mutation rate.
A comparison between the Rm(X)-IG constructs, with positive selection by FACS, and
between the G(X)-IP and Rm(X)-IN constructs [Klasen et al., 2004], with negative
selection by drugs, showed that enhancers had an influence on the mutation rate in the
case where there was no drug selection. A simple explanation for this could be that the
enhancer elements increase transcription rates which, in turn, results in higher mutation
rates. In drug selection, a high selection pressure results in a high transcription rate,
because cells that are not resistant just die. However, although in my experiments it did
not increase the transcription rate of the reporter construct (as measured by the relative
GFP fluorescent intensity), the SV40 enhancer mediated a high mutation rate. Because
the SV40 enhancer was placed directly 3' to the reporter DsRed gene and 5' to the IRES-
GFP selection marker, it might be that the SV40 enhancer increases transcription
initiation at the promoter, and at the same time inhibits the initiation of translation at the
IRES element. Indeed, interference between IRES elements and other cis-acting elements
has been reported [Chappell et al., 2000]. On the other hand enhancer elements, e. g.,
matrix attachment regions, may form secondary structures that lead to a pause in
transcription [Fernandez et al., 2001; Wiersma et al., 1999]. Hypothetically, structurally
framing a target DNA sequence between a promoter and an enhancer element could
cause a pause in transcription. This would keep AID in close proximity to an exposed
ssDNA within the transcription bubble for a longer period of time, which could result in
an increased mutational load per transcription initiation [Peters and Storb, 1996; Pham et
al., 2003]. But very high transcription rates could compensate for the necessity of an
enhancer. The different influences of the Eµ enhancer in our antibiotic resistance selected
constructs compared to the GFP selected constructs may be seen as circumstantial
evidence for this hypothesis. In conclusion, depending on their position in these
ectopically expressed constructs and the transcription rate, enhancers can have positive or
negative effects on hypermutation.
4.3. Specific Aim 3: Somatic hypermutation and mismatch repair in non-B cells
4.3.1. Hypermutation rate in the 293T cell line
By regulating expression of MLH1, which is essential in mismatch repair, in the 293T
kidney cell line that had been transduced by an AID containing vector no difference in
mutation rates of an indicator gene was found, whether or not MLH1 was expressed.
In the 293T cell line, AID is not phosphorylated [Chaudhuri et al., 2004]. In a cell free
system, AID purified from ectopic expression in the 239T cell line could deaminate
single stranded DNA, but had little deamination activity on the RGYW motif [Chaudhuri
et al., 2004]. One would, therefore, expect a low mutation rate in this cell line. With 4 x
10-6 mutations per bp per day, the frequency does not seem to be so low. However, to
estimate a rate one needs to take into account (i) the copy number of the GFP* reporter
gene; and (ii) the number of cell divisions per day. For my experiment, the average GFP*
copy number per cell was measured by quantitative PCR [Spillmann, personal
communication] and it was found that it contained 1.6 times as many GFP* gene copies
as our standard transduced 18-81 cell line, with one copy of GFP* per cell. I thus divide
the frequency of 4 x 10-6 mutations per bp per day by the factor 1.6, which yields a
frequency of 2.5 x 10-6 mutations per bp per day.
Now the question arises whether to give rates per day or per cell generation. It is
generally believed that in B cells undergoing Ig somatic hypermutation, more cell
divisions result in more mutations. This is because DNA synthesis and replication is
thought to play a role in the known mutation mechanisms—cytidine deamination and
subsequent conversion to thymidine, uracil-DNA glycosylase-mediated repair, DNA
mismatch repair, and DNA synthesis by error prone polymerases. If the above number of
2.5 x 10-6 mutations per bp per day was converted into a rate per cell generation, one
would have to divide it by the number of cell generation per day. Due to the drug
selection pressure, the transduced 239T cells divided every 74 hours, i.e., with 0.32
generations per day. I thus would arrive at 7.8 x 10-6 mutations per bp per cell
generation—still much higher than the normal, spontaneous point mutation rate.
However, in recent experiments we found that the frequency of mutants does not
necessarily increase with the number of cell generations [Wang et al., 2004; Bachl et al.,
1999; Wang, personal communication]. On the contrary, a greater number of divisions
can lead to a lower frequency of mutants. Our results indicate that cell division is not a
rate-limiting step in the hypermutation process. We, therefore, suggested that the
mutation rate is governed primarily by the rate of DNA transcription and the activity of
AID. If so, one needs to compare the rate of 2.5 x 10-6 mutations per bp per day to the one
of 1 x 10-5 mutations per bp per day for the ectopic GFP* in the 18-81 cell line [Bachl
and Wabl, 1996].
4.3.2. Conclusion
In this thesis, rather than on the activity of AID, we focused on the function of MMR on
hypermutation in cells other than activated B lymphocytes. In hypermutating B cells, the
loss of MMR proteins, such as MLH1 and PMS2, results in a reduction of the mutation
frequencies and in a change of the mutation pattern [Winter et al., 1998, Chaudhuri et al.,
2004; Phung et al., 1999]. Consequently, we and others suggested an active contribution
of MMR to hypermutation, for example fixing [Cascalho et al., 1998; Shannon and
Weigert, 1998] or introducing [Li et al., 2004; Woo et al., 2003] base mismatches.
Physical association of MLH1 and Exo1 to the Ig V-region, but not the Ig C-region in
hypermutating BL2 cells support this idea [Li et al., 2004; Woo et al., 2003]. However,
there is no reason to expect “reverse repair” in non-B lymphocytes. Here I find no
difference in mutation frequencies, whether or not MMR is functional. Because in both
cases mutations do persist at a rate still much higher than the normal, spontaneous
mutation rate, I conclude that in cells other than hypermutating B cells, MMR is
overwhelmed and thus does not correct mutations in a noticeable way. A corollary of this
conclusion would be that hypermutating B cells contain specific factor(s) that modify
mismatch repair.
5. Summary
Somatic hypermutation in the Ig genes is a paradigm of a site-specific, stage-specific,
lineage-specific "mutator system" that generates point mutations at high rates at the Ig
locus in an AID mediated and transcription dependent manner during affinity maturation
of activated B-cells. The questions in the field of hypermutation today are (i) what targets
the mutator factors to the Ig genes? And (ii) what are these factors?
To address some aspects of these questions, I engineered and compared retroviral vectors
to monitor hypermutation. Retroviral vectors combine a high transduction rate with
integration at random sites within the host cell genome, thus equalizing positional effects
on the reporter gene. The vectors contain a reporter gene with a premature TAG
termination codon; upon reversion, a full-length fluorescent protein is expressed. The
number of fluorescent cells can be easily measured in flow cytometry, and thus mutation
frequencies can be determined with accuracy. I tested the green and yellow fluorescence
proteins (GFP and YFP); and various proteins with red fluorescence (dsRed).
Furthermore, I tested various selection markers to select for transduced cells. I found that
GFP as a reporter, combined with a drug selection marker, gave the most consistent and
convenient mutation rate measurements. DsRed is a good alternative to GFP, but variants
with greater fluorescence intensity are needed when combined with green fluorescence
measurements.
To study the activity of enhancers on transcription and hypermutation, I introduced
various cis-acting enhancer elements into the reporter construct. Using such constructs I
found that no immunoglobulin specific sequence is needed to target hypermutation. Also,
depending on their position in these ectopically expressed constructs and on the
transcription rate, enhancers can have positive or negative effects on hypermutation.
I also applied the indicator system to investigate whether or not mismatch repair
influences AID mediated hypermutation in a non-B lymphocyte line. To do so MLH 1
expression, which is essential in mismatch repair, was regulated in a non-lymphocyte cell
line that had been transduced by an AID containing vector. Whether or not MLH1 was
expressed, we found no difference in mutation rates of an indicator gene. This is in
contrast to activated B cells, where the absence of mismatch repair results in a reduction
of hypermutation. I, therefore, conclude that in order to contribute to hypermutation,
mismatch repair needs additional factors that are present in activated B lymphocytes but
absent in the cell line investigated.
During my cloning efforts to create DsRed containing indicator vectors, I found that a
single base substitution that does not change the amino acid sequence in the gene
encoding DsRed2 resulted in an increase in relative fluorescence intensity of the protein.
Surprisingly, the mutated codon is slightly less favored than the original one and,
therefore, would be expected to have a negative effect on fluorescence intensity, if any at
all. I suggest that in highly expressed genes, the tRNA with the anticodon corresponding
to a commonly used codon might become depleted. As a consequence, overall less
protein is synthesized, but mRNAs using less frequent codons at some positions may be
translated more efficiently.
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